Page last updated: 2024-12-07

sulbactam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID130313
CHEMBL ID403
CHEBI ID9321
SCHEMBL ID47781
MeSH IDM0020733

Synonyms (111)

Synonym
smr000387064
MLS001048859
AC-18973
AB00698109-08
cp-458992
(2s,5r)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
C07770
68373-14-8
sulbactam ,
(2s,5r)-3,3-dimethyl-4,4,7-trioxo-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-,4,4-dioxide, (2s, cis)
NCGC00159336-02
cp-45899
(2s,5r)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure 4,4-dioxid
(2s,5r)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide
cp 45899
sulbactamum [inn-latin]
penicillanic acid sulfone
sulbactam [inn:ban]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2s-cis)-
einecs 269-878-2
MLS001304017
sulbactamum
CHEBI:9321 ,
penicillanic acid 1,1-dioxide
2,2-dimethyl-1,1-dioxidopenam-3alpha-carboxylic acid
HMS2090E07
nsc-759886
CHEMBL403 ,
sulbactam (inn)
D08533
STK801889
(2s,5r)-3,3-dimethyl-4,4,7-trioxo-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
cp-45,899
(s)-3,3-dimethyl-7-(r)-oxo-4,4-dioxo-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
3,3-dimethyl-4,4,7-trioxo-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid
3,3-dimethyl-4,4,7-trioxo-4lambda*6*-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid (sulbactam)
bdbm50021954
(2s,5r)-3,3-dimethyl-4,4,7-tris(oxidanylidene)-4$l^{6}-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
A836122
AKOS004119988
NCGC00159487-06
cp45899
sulfone, penicillanic acid
S0868
sulbactam acid
(2s,5r)?-?3,3-?dimethyl-?7-?oxo-?4-?thia-?1-?azabicyclo[3.2.0]?heptane-?2-?carboxylic acid 4,4-dioxide
betamaze
s4tf6i2330 ,
nsc 759886
unii-s4tf6i2330
cas-68373-14-8
dtxsid1023605 ,
tox21_113642
dtxcid503605
0rn ,
HMS2269A12
NCGC00159336-05
S1958
sulbactam [mart.]
sulbactam [usp-rs]
sulbactam [who-dd]
sulbactam [vandf]
sulbactam [inn]
sultamicillin impurity a [ep impurity]
sulbactam [mi]
CCG-221124
BBL033518
HY-B0334
SCHEMBL47781
AB00698109-06
tox21_113642_1
NCGC00159336-03
KS-5198
FKENQMMABCRJMK-RITPCOANSA-N
AB00698109_09
mfcd00867005
DB09324
sulbactam, analytical reference material
(2s,5r)-3,3-dimethyl-4,4,7-trioxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SR-01000760610-3
sr-01000760610
SR-01000760610-2
sulbactam, united states pharmacopeia (usp) reference standard
HMS3651C06
sulbactam, european pharmacopoeia (ep) reference standard
sulbactam for peak identification, european pharmacopoeia (ep) reference standard
HMS3715B09
Z1563146038
(2s,5r)-3,3-dimethyl-4,4,7-trioxo-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Q423393
68373-14-8 (free acid)
sulbactam,(s)
sulbactam 100 microg/ml in acetonitrile
BCP13271
sulbactam (sodium salt)
betamaze sodium salt;cp45899 sodium salt
BRD-K44133266-001-10-0
(2s,5r)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
EN300-122646
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid,3,3-dimethyl-7-oxo-, 4,4-dioxide, (2s,5r)-
gtpl10769
EX-A2000
sulbactam; sulbactam acid
BS167314
(2s,5r)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid4,4-dioxide
sultamicillin impurity a (ep impurity)
sulbactam (usp-rs)
sulbactamum (inn-latin)
j01cg01
sulbactam (mart.)

Research Excerpts

Overview

Sulbactam-durlobactam is a beta-lactamase inhibitor with limited oral bioavailability. It is currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates.

ExcerptReferenceRelevance
"Sulbactam (1) is a beta-lactamase inhibitor with limited oral bioavailability. "( Orally effective acid prodrugs of the beta-lactamase inhibitor sulbactam.
English, AR; Girard, D; Jasys, VJ; Kellogg, MS; Martingano, RJ, 1990
)
1.96
"Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in development for the treatment of infections caused by Acinetobacter, including multidrug-resistant (MDR) isolates. "( The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex.
Bhavnani, SM; O'Donnell, JP, 2023
)
2.58
"Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination in late-stage development for the treatment of Acinetobacter infections, including those caused by multidrug-resistant strains. "( Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.
McLeod, SM; Miller, AA; Papp-Wallace, KM, 2023
)
2.59
"Sulbactam-durlobactam is a potent combination active against Acinetobacter baumannii; however, it lacks activity against other nosocomial pathogens. "( In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales.
Fouad, A; Gill, CM; Nicolau, DP, 2023
)
2.62
"Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii."( In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China.
Bradford, PA; Deng, J; Hackel, M; Jia, P; Reinhart, H; Xu, Y; Yang, Q; Zhang, G; Zhang, J; Zhu, Y, 2020
)
1.6
"Sulbactam is a plausible option for treating "( Molecular Epidemiology and Mechanism of Sulbactam Resistance in Acinetobacter baumannii Isolates with Diverse Genetic Backgrounds in China.
Chen, Y; Fu, Y; Hua, X; Ji, S; Jiang, Y; Lan, P; Ruan, Z; Xu, Q; Yang, Y; Yu, Y, 2018
)
2.19
"Sulbactam is an effective antimicrobial agent against multidrug-resistant Acinetobacter spp. "( Risk factors and clinical outcome of sulbactam nonsusceptibility in monomicrobial Acinetobacter nosocomialis bacteremia.
Chang, YY; Chen, TL; Fung, CP; Kuo, SC; Lai, HH; Lee, YT; Liou, BH, 2016
)
2.15
"Sulbactam is a class A β-lactamase inhibitor with intrinsic whole-cell activity against certain bacterial species, including Acinetobacter baumannii. "( Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.
DeJonge, BL; Ehmann, DE; Gao, N; Giacobbe, RA; Gu, RF; Huband, MD; McLaughlin, RE; Miller, AA; Penwell, WF; Shapiro, AB; Thresher, J, 2015
)
2.17
"Sulbactam is a β-lactamase inhibitor with antimicrobial activity against MDR Acb complex."( Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Cheng, CW; Hsu, PC; Huang, CT; Lee, MH; Leu, HS; Lin, HS; Ye, JJ, 2015
)
2.58
"Sulbactam is a mechanism-based inhibitor of beta-lactamase enzymes used in clinical practice. "( Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
Bonomo, RA; Buynak, JD; Carey, MP; Carey, PR; Helfand, MS; Sheri, A; Totir, MA, 2007
)
3.23
"Sulbactam/ampicillin is an effective and well tolerated antimicrobial agent in the prophylaxis of post-surgical infections."( [The efficacy of sulbactam-ampicillin in preventing postoperative infections in gynecology and obstetrics. A comparative open study].
Ahued Ahued, R; Leal del Rosal, JA; Rocha del Valle, G; Sereno Colo, JA, 1994
)
1.35
"Sulbactam is a beta-lactamase inhibitor that, when combined with ampicillin, extends its antibacterial activity against beta-lactamases producing organisms. "( [An open comparative study of sulbactam/ampicillin vs mezlocillin in adult and pediatric patients. Efficacy and tolerability].
Chiodo, F; Manfredi, R; Zucchini, A, 1991
)
2.01
"Sulbactam is a new beta-lactamase inhibitor. "( Pharmacokinetics of sulbactam and ampicillin in mice and in dogs.
Liu, CX; Lu, YL; Wang, JR, 1990
)
2.05
"Sulbactam is a semisynthetic beta-lactamase inhibitor which, in combination with ampicillin, extends the antibacterial activity of the latter to include some beta-lactamase-producing strains of bacteria that would otherwise be resistant."( Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Campoli-Richards, DM; Friedel, HA; Goa, KL, 1989
)
1
"Sulbactam/ampicillin is a safe and effective antibiotic for the treatment of common pediatric infections."( Intravenous sulbactam/ampicillin in the treatment of pediatric infections.
Chen, CM; Chu, ML; Hsu, CY; Huang, LM; Lee, CY; Lee, MJ; Lin, TY,
)
1.23
"Sulbactam (SBT) is a new derivative of the basic penicillin nucleus. "( [Clinical efficacy of sulbactam/ampicillin in the field of pediatrics].
Hisakawa, H; Kawakubo, K; Kubota, H; Kurashige, T; Matsumoto, K; Ogura, H; Shimanouchi, Y; Tomoda, T; Tone, Y, 1989
)
2.03
"Sulbactam was found to be an effective antimicrobial agent against Acinetobacter species (MIC50, 1.0 microgram/ml), Pseudomonas acidovorans (MIC50, 2.0 micrograms/ml), Neisseria gonorrhoeae (MIC50, less than or equal to 0.5 microgram/ml), and N."( In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.
Barry, AL; Jones, RN; Thornsberry, C; Wilson, HW, 1985
)
1.25
"Sulbactam/ampicillin is a viable alternative for the treatment of women with acute pelvic infections."( Sulbactam/ampicillin for treatment of polymicrobial pelvic infections.
Hemsell, DL, 1986
)
2.44
"Sulbactam is a time-dependent irreversible inhibitor of various beta-lactamases by reversible formation of a Michaelis-type enzyme-inhibitor complex and progressive evolution of this complex into inactivated protein(s). "( Sulbactam: biochemical factors involved in its synergy with ampicillin.
Kazmierczak, A; Labia, R; Lelievre, V; Mattioni, D; Morand, A,
)
3.02
"Sulbactam is a beta-lactamase inhibitor that, when combined with ampicillin, gives the latter antibiotic a broad spectrum of activity, making it suitable for use as a prophylactic agent in acute appendicitis. "( A randomized comparative study of sulbactam plus ampicillin vs. metronidazole plus cefotaxime in the management of acute appendicitis in children.
Foster, MC; Kapila, L; Morris, DL; Slack, RC,
)
1.85
"Sulbactam is a new beta-lactamase inhibitor with pharmacokinetic characteristics in humans similar to those of ampicillin. "( Clinical efficacy and safety of sulbactam/ampicillin in patients suffering from chronic liver disease.
Barba, D; Esposito, S; Galante, D; Ruffilli, MP, 1987
)
2
"Sulbactam is a semisynthetic beta-lactamase inhibitor which when combined with certain beta-lactam antibacterials extends their activity against bacteria that are normally resistant to the antibiotic due to production of beta-lactamases. "( Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
Brogden, RN; Campoli-Richards, DM, 1987
)
3.16
"Sulbactam/ampicillin is a combination of a beta-lactamase inhibitor with minimal intrinsic antibacterial activity (sulbactam sodium), and an aminopenicillin (ampicillin sodium). "( Sulbactam/ampicillin, a new beta-lactamase inhibitor/beta-lactam antibiotic combination.
Benson, JM; Nahata, MC,
)
3.02
"Sulbactam is a competitive, irreversible beta-lactamase inhibitor."( Sulbactam: a beta-lactamase inhibitor.
Gill, MA; Noguchi, JK, 1988
)
2.44
"Sulbactam is a beta-lactamase inhibitor, which when administered with ampicillin, increases the latter agents antibacterial activity against beta-lactamase producing organisms. "( Perioperative prophylaxis with sulbactam and ampicillin compared with metronidazole and cefotaxime in the prevention of wound infection in children undergoing appendectomy.
Foster, MC; Kapila, L; Legan, C; Morris, DL; Slack, RC, 1987
)
2
"Sulbactam-ampicillin is a combination of sulbactam, a beta-lactamase inhibitor, and ampicillin, a broad spectrum beta-lactam antibiotic. "( Efficacy of sulbactam-ampicillin in the treatment of neonatal calf diarrhoea.
Colman, PJ; Grimshaw, WT; Petrie, L, 1987
)
2.09
"Sulbactam-ampicillin is a combination of sulbactam, a beta-lactamase inhibitor, and ampicillin, a broad spectrum beta-lactam antibiotic. "( The efficacy of sulbactam-ampicillin in the therapy of respiratory disease associated with ampicillin resistant Pasteurella species in housed calves.
Colman, PJ; Grimshaw, WT; Weatherley, AJ, 1987
)
2.06

Effects

Sulbactam has the potential to be a useful addition to the limited armamentarium of drugs that can be used to treat this problem pathogen. It has been used primarily to protect ampicillin from enzymatic hydrolysis.

ExcerptReferenceRelevance
"Sulbactam/durlobactam has the potential to become a useful addition to the limited armamentarium of drugs that can be used to treat this problem pathogen."( In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.
Higgins, PG; Kresken, M; Miller, A; Müller, C; Seifert, H; Stefanik, D, 2020
)
1.6
"Sulbactam alone has good intrinsic activity against carbapenem-resistant Acinetobacter strains sometimes even in the presence of carbapenemase genes, suggesting unsteady levels of carbapenemases."( Cefoperazone/sulbactam: New composites against multiresistant gram negative bacteria?
Ku, YH; Yu, WL, 2021
)
1.71
"Sulbactam has good in vitro activity against Acinetobacter organisms; thus, ampicillin-sulbactam (Amp-Sulb) may be a viable treatment alternative."( Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia.
Boucher, BA; Croce, MA; Fabian, TC; Hanes, SD; Wood, GC, 2002
)
1.34
"Sulbactam has been used primarily to protect ampicillin from enzymatic hydrolysis."( Beta-lactamase inhibitors from laboratory to clinic.
Bush, K, 1988
)
1

Actions

Sulbactam was shown to increase the susceptibility of various unselected Gram-negative bacilli. This effect increased with larger concentrations of sulbactsam. SulbactAm can not enhance the activity of ceftazidime against Enterobacter cloacae.

ExcerptReferenceRelevance
"Sulbactam can not enhance the activity of ceftazidime against Enterobacter cloacae. "( [The inducibility of Amp C enzyme of Enterobacter cloacae and its susceptibility to enzyme inhibitor].
Li, J; Zhang, Y; Zhao, M, 2001
)
1.75
"Sulbactam was shown to increase the susceptibility of various unselected Gram-negative bacilli; this effect increased with larger concentrations of sulbactam."( In vitro assessment of sulbactam plus cefoperazone in the treatment of bacteria isolated from cancer patients.
Bodey, GP; Ho, DH; Miller, P,
)
1.16

Treatment

Sulbactam could be a treatment option for pneumonia involving MDR Acb complex. combination therapy with carbapenems could be considered for sul bactam-resistant cases. SulbactAM pretreatment significantly upregulated GLT1 expression in sham rats.

ExcerptReferenceRelevance
"Sulbactam pretreatment significantly upregulated GLT1 expression in sham rats and prevented or reversed the GLT1 downregulation normally induced in the ischemic rat brain."( Sulbactam Plays Neuronal Protective Effect Against Brain Ischemia via Upregulating GLT1 in Rats.
Cui, X; Hu, YY; Li, L; Li, WB; Ren, S; Zhang, M, 2015
)
2.58
"Sulbactam could be a treatment option for pneumonia involving MDR Acb complex, and combination therapy with carbapenems could be considered for sulbactam-resistant cases."( Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Cheng, CW; Hsu, PC; Huang, CT; Lee, MH; Leu, HS; Lin, HS; Ye, JJ, 2015
)
3.3
"Sulbactam/ampicillin treatment was rated excellent in 87.5% of cases and good in 6.3%."( Clinical experience with intramuscular sulbactam/ampicillin in the outpatient treatment of various infections. A multicentre trial.
Güneren, MF, 1988
)
1.27
"Treatment with sulbactam-ampicillin was compared with treatment with ampicillin alone in 123 Friesian calves, between three and five weeks old, exhibiting clinical signs of respiratory disease."( The efficacy of sulbactam-ampicillin in the therapy of respiratory disease associated with ampicillin resistant Pasteurella species in housed calves.
Colman, PJ; Grimshaw, WT; Weatherley, AJ, 1987
)
0.96

Toxicity

Ampicillin/sulbactam and cefuroxime provide safe and effective parenteral antibiotic therapy in pediatric patients with serious skin and skin structure infections.

ExcerptReferenceRelevance
" Tolerability of sultamicillin was good and only three possible or probable treatment-related adverse events were recorded."( An open non-comparative pilot study of the safety and efficacy of oral sultamicillin in the treatment of mild to moderate upper respiratory tract infections in children.
Argüello, A, 1992
)
0.28
" Study drug-related adverse events were experienced by 33."( An open comparative study of the efficacy and safety of sultamicillin versus cefaclor in the treatment of acute otitis media in children.
Biolcati, AH, 1992
)
0.28
" Gastrointestinal adverse events occurred in both treatment groups (eight sultamicillin-treated patients and three cefuroxime axetil-treated patients); one patient receiving cefuroxime axetil discontinued treatment due to nausea."( An open multicentre study to compare the efficacy and safety of sultamicillin with that of cefuroxime axetil in acute ear nose and throat infections in adults.
Alvart, R, 1992
)
0.28
" Adverse reactions to oral therapy were minimal."( Efficacy and safety of sequential treatment with parenteral sulbactam/ampicillin and oral sultamicillin for skeletal infections in children.
Aronoff, SC; Blumer, JL; Jacobs, MR; Kalamchi, A; Makley, JT; Scoles, PV,
)
0.37
" Adverse reactions were infrequent with the exception of injection-site pain, which occurred mainly after intramuscular injection and was reduced in incidence by concurrent administration of lidocaine."( Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use.
Greenhalgh, K; Knirsch, AK; Lees, L; Milson, JA,
)
1.57
" Mild or moderate side effect (allergic reaction including rash etc."( [Efficacy and safety of sulbactam/cefoperazone for hepato-biliary infections].
Amako, Y; Fujisaki, M; Hirano, M; Ishii, J; Itakura, M; Iwasa, T; Kako, M; Koyama, M; Mitamura, K; Nakaya, S; Nishio, T; Ohswawa, N; Ohyama, R; Okuda, K; Oohira, S; Saito, H; Shinagawa, N; Sugiyama, A; Takashima, S; Takeda, S; Ueda, M; Yamada, M; Yasuda, Y; Zeze, F, 1997
)
0.6
"Both ampicillin/sulbactam and cefuroxime provide safe and effective parenteral antibiotic therapy in pediatric patients with serious skin and skin structure infections."( Efficacy and safety of ampicillin/sulbactam and cefuroxime in the treatment of serious skin and skin structure infections in pediatric patients. UNASYN Pediatric Study Group.
Azimi, PH; Barson, WJ; Janner, D; Swanson, R, 1999
)
0.93
"To evaluate the utilization of antibacterial drugs and their adverse effects in patients admitted for respiratory disease based on medical record review."( [Survey of the utilization and adverse effects of antibacterial drugs in patients admitted for respiratory diseases].
Chen, Y; Xu, J; Zhang, Q; Zheng, P, 2005
)
0.33
" The drug utilization index (DUI) and daily cost of antibacterial drugs were calculated, with also assessment of the adverse effects in relation to the drug use."( [Survey of the utilization and adverse effects of antibacterial drugs in patients admitted for respiratory diseases].
Chen, Y; Xu, J; Zhang, Q; Zheng, P, 2005
)
0.33
"3 RMB, with a total of 14 cases with adverse drug effects recorded."( [Survey of the utilization and adverse effects of antibacterial drugs in patients admitted for respiratory diseases].
Chen, Y; Xu, J; Zhang, Q; Zheng, P, 2005
)
0.33
" Drug-related adverse events for both study drugs were comparable in frequency and type."( An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
Boghossian, J; Caputo, W; Dana, A; Gray, S; Harkless, L; Pollak, R; Wu, D, 2005
)
0.54
"Although both study drugs provide safe and effective empiric treatment for moderate-to-severe infected diabetic foot ulcers, piperacillin/tazobactam has the advantage of covering Pseudomonas aeruginosa (bacteriologic success rate of 85."( An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers.
Boghossian, J; Caputo, W; Dana, A; Gray, S; Harkless, L; Pollak, R; Wu, D, 2005
)
0.54
" The adverse events ratio for the two groups was the same (p=0."( Efficacy and safety of Sultamicillin (Ampicillin/Sulbactan) and Amoxicillin/Clavulanic acid in the treatment of upper respiratory tract infections in adults--an open-label, multicentric, randomized trial.
Ferreira, JB; Kós, AO; Mocellin, M; Pignatari, SS; Piltcher, OB; Pinheiro, SD; Rapoport, PB; Sakano, E,
)
0.13
"Ampicillin/Sulbactan is as safe and efficient as Amoxicillin/Clavulanate in the empiric treatment of upper respiratory infections in adults."( Efficacy and safety of Sultamicillin (Ampicillin/Sulbactan) and Amoxicillin/Clavulanic acid in the treatment of upper respiratory tract infections in adults--an open-label, multicentric, randomized trial.
Ferreira, JB; Kós, AO; Mocellin, M; Pignatari, SS; Piltcher, OB; Pinheiro, SD; Rapoport, PB; Sakano, E,
)
0.13
" Adverse events were 39."( Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
Betrosian, AP; Douzinas, EE; Frantzeskaki, F; Xanthaki, A, 2008
)
0.61
" Except for this serious adverse event, both the study medications were safe and well tolerated in the study population."( Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections.
Chandurkar, N; Daga, S; Deshpande, A; Kulkarni, M; Pareek, A, 2008
)
0.59
" All treatment-related adverse events were mild or moderate in severity."( Efficacy and safety of intravenous sulbactam/ampicillin 3 g 4 times daily in Japanese adults with moderate to severe community-acquired pneumonia: a multicenter, open-label, uncontrolled study.
Itamura, R; Kadota, J; Kohno, S; Mikamo, H; Niki, Y; Tateda, K, 2015
)
0.69
" No significant differences in adverse events were observed between groups."( Effectiveness and Safety of Generic Formulation of Cefoperazone/Sulbactam (Bacticep®) in Treatment of Infections at Siriraj Hospital.
Koomanachai, P; Thamlikitkul, V; Tongsai, S, 2016
)
0.67
" The objective of this study was to investigate the efficacy of this drug in patients with Extended Spectrum Beta Lactamases/Metallo Beta lactamases infections and identify the incidence of adverse events in real clinical settings."( Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Ayub, SG; Chaudhary, M; Mir, MA,
)
0.38
" Information regarding demographic, clinical and microbiological parameters, dosage and treatment duration, efficacy and adverse events (AEs) associated with the treatment were recorded."( Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Ayub, SG; Chaudhary, M; Mir, MA,
)
0.38
"In this post-marketing surveillance study, CSE-1034 was found to be an effective and safe option against Pip tazo and meropenem in management of patients with multi-drug resistant (MDR) bacterial infections under routine ward settings."( Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Ayub, SG; Chaudhary, M; Mir, MA,
)
0.38
" Secondary outcomes were all-cause mortality and nephrotoxic and non-nephrotoxic adverse events."( Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis.
Apisarnthanarak, A; Chaiyakunapruk, N; Kengkla, K; Kongpakwattana, K; Saokaew, S, 2018
)
0.48
" The primary outcome was treatment success without modification, and the secondary outcomes were all-cause mortality and adverse events (AEs)."( Efficacy and safety of cefoperazone-sulbactam in empiric therapy for febrile neutropenia: A systemic review and meta-analysis.
Chang, SP; Lai, CC; Lan, SH; Lu, LC; Tang, HJ, 2020
)
0.83
"Although 12 g/day sulbactam/ampicillin (SBT/ABPC) is approved in Japan, differences in the frequency of adverse effects induced by conventional (≤6 g/day) and high (≥9 g/day) doses remain unclear."( Comparison of safety between high and low doses of sulbactam/ampicillin: A retrospective observational study in Japanese patients with pneumonia.
Imanishi, K; Miyabe, T; Nakakura, I; Sako, R; Yamauchi, K, 2020
)
1.14

Pharmacokinetics

Ampicillin-sulbactam (2:1) was tested against Escherichia coli and Bacteroides fragilis. The half-life of sulbactsam (like that of ampicillin) was altered in the elderly.

ExcerptReferenceRelevance
" Pharmacokinetic parameters were determined by noncompartmental methods."( Effect of impaired renal function on the pharmacokinetics of coadministered cefoperazone and sulbactam.
Bawdon, RE; Castle, S; Norman, DC; Rho, JP; Smith, K, 1992
)
0.5
" Several serum pharmacokinetic parameters were similar for the two drugs after three intravenous doses were given to patients following surgery."( Pharmacokinetics of ampicillin and sulbactam in patients undergoing heart surgery.
Müller, V; Sonntag, HG; Springsklee, M; Wildfeuer, A, 1991
)
0.56
" The model provides simulation of the pharmacokinetic profiles of the drug observed after its intra-muscular and intravenous administration in rats and humans."( [Physiological model of sulbactam pharmacokinetics in rats and humans. Distribution of sulbactam in the tissues after intravenous and intramuscular administration].
Manuĭlov, KK, 1991
)
0.59
" The pharmacodynamic activity of this drug was also determined by use of mean bactericidal titers against selected bacterial strains."( Ampicillin and sulbactam pharmacokinetics and pharmacodynamics in continuous ambulatory peritoneal dialysis (CAPD).
Blackwell, BG; Craig, WA; Johnson, CA; Leggett, JE; Zimmerman, SW, 1990
)
0.63
" The pharmacokinetic characteristics of sulbactam was similar to ampicillin after a single intravenous injection of 200 mg/kg in mice with a half-life of approximately 50 min."( Pharmacokinetics of sulbactam and ampicillin in mice and in dogs.
Liu, CX; Lu, YL; Wang, JR, 1990
)
0.87
"We investigated the pharmacokinetic properties of sulbactam/ampicillin (S/A), after intravenous (0."( Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection.
Ferrante, L; Prenna, M; Ripa, S, 1990
)
0.86
" The pharmacokinetic parameters for both ampicillin and sulbactam were calculated by computer-based two-compartment nonlinear model."( Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects.
Bawdon, RE; Castle, S; Jones, A; Norman, DC; Rho, JP; Smith, K; Woo, M, 1989
)
0.77
" The pharmacokinetic parameters of the two components are similar, both being eliminated primarily by renal excretion."( The pharmacokinetics of sultamicillin.
Bruckner, G; Hampel, B; Koeppe, P; Lode, H, 1989
)
0.28
" For pharmacokinetic investigation, SBT/ABPC at 30 or 60 mg/kg was administered by intravenous drip infusion over 30 minutes."( [Pharmacokinetic and clinical studies on sulbactam/ampicillin in the pediatric field].
Imamura, H; Nakayama, N; Tsuji, Y; Yanagi, T; Yanagishima, M; Yanai, M, 1989
)
0.54
" The relevant pharmacokinetic parameters of the single substances were essentially unchanged when administered in combination."( Studies on the synergism of sulbactam and beta-lactam antibiotics under in vitro conditions and in healthy volunteers after intravenous administration. Antibacterial activity in vitro, compatibility and pharmacokinetics of the drugs in combination.
Eibel, G; Pfaff, G; Räder, K; Schmalreck, A; Wildfeuer, A, 1989
)
0.57
" In hemodialysis patients, the ampicillin half-life was 17."( Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
Blum, RA; Harrison, NJ; Kohli, RK; Schentag, JJ, 1989
)
0.53
" Although the kinetics of sulbactam in postpartem women and in surgical patients were similar to the kinetics in young men, the half-life of sulbactam (like that of ampicillin) was altered in the elderly, during labor, in neonates, and in patients with renal impairment."( Pharmacokinetics of sulbactam/ampicillin in humans: a review.
Foulds, G,
)
0.75
" Noncompartmental and compartmental calculations resulted in similar pharmacokinetic parameters."( Single-dose pharmacokinetics of intravenous sulbactam in pediatric patients.
Guenin, K; Schaad, UB; Straehl, P,
)
0.39
" The basic pharmacokinetic characteristics of sulbactam after parenteral administration are similar to those of ampicillin."( Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
Brogden, RN; Campoli-Richards, DM, 1987
)
1.97
" The two drugs showed a similar pharmacokinetic profile in humans."( Pharmacokinetics of sulbactam and ampicillin intravenously applied in combination to healthy volunteers and patients. Determination of the ratio of the two drugs in serum and in various tissues.
Engel, K; Lenders, H; Potempa, J; Schilling, A; Schwiersch, U; von Castell, E; Wildfeuer, A, 1988
)
0.6
"In this study, the pharmacokinetic parameters of 2 different beta-lactamase inhibitors (sulbactam and clavulanic acid) in combination with 2 different aminobenzylpenicillins (ampicillin and amoxycillin) were compared."( Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers.
Bruckner, G; Hampel, B; Koeppe, P; Lode, H, 1988
)
0.78
" A study has been performed to evaluate pharmacokinetic properties and clinical usefulness of SBTPC fine granules in the treatment of pediatric infections."( [Clinical and pharmacokinetic studies on sultamicillin fine granules in pediatrics].
Matsumoto, K; Nakanishi, Y; Nakazawa, S; Narita, A; Niino, K; Sato, H; Suzuki, H, 1988
)
0.27
" Pharmacokinetic studies were done in 2 subjects (a male and a female) following single oral administrations of 5 mg/kg and 10 mg/kg SBTPC fine granules after meal."( [A study on pharmacokinetics, antimicrobial activity and clinical efficacy of sultamicillin in children].
Higashino, H; Hirabayashi, Y; Kitamura, N; Kobayashi, Y; Okazaki, H, 1988
)
0.27
" Pharmacokinetic and clinical studies using SBTPC 10% fine granules were performed in pediatric patients with a variety of infections."( [Pharmacokinetic and clinical studies of sultamicillin fine granules in children].
Hayashi, K; Imamura, H; Nakayama, N; Tsuji, Y; Yanagi, T; Yanagishima, M; Yanai, M, 1988
)
0.27
" In addition, the pharmacodynamic profile of this combination was determined by the use of mean bactericidal titers against selected bacterial strains."( Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.
Craig, WA; Johnson, CA; Leggett, JE; Reitberg, DP; Whall, TJ; Zimmerman, SW, 1988
)
0.52
" No cefoperazone pharmacokinetic parameters were appreciably altered by renal failure or hemodialysis, and there was no correlation between the total body clearance of cefoperazone and estimated creatinine clearance."( Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
Marble, DA; Reitberg, DP; Schentag, JJ; Schultz, RW; Whall, TJ, 1988
)
0.53
" Mean estimates of cefoperazone maximal concentration in plasma (Cmax), area under the curve of drug concentration in plasma versus time (AUC), half-life (t 1/2), apparent volume of distribution by the area method (Varea), apparent volume of distribution at steady state (Vss), and total body clearance (CL) for day 1 (day 5) were 297."( Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients.
Bachmann, KA; Jauregui, LE; Martin, ME; Reitberg, DP; Schwartz, JI, 1988
)
0.5
"Sulbactam, a new beta-lactamase inhibitor, has pharmacokinetic characteristics in humans similar to those of ampicillin and amoxicillin."( Pharmacokinetics of sulbactam in humans.
Foulds, G; Hayes, SL; Marshall, DC; McMahon, FG; O'Brien, MM; Stankewich, JP; Weidler, DJ, 1983
)
2.03
"To compare the pharmacokinetic and pharmacodynamic activity of three drug regimens: cefotaxime plus metronidazole, cefoxitin, and ampicillin-sulbactam against two organisms frequently isolated in intraabdominal infection, Escherichia coli and Bacteroides fragilis."( Comparison of the pharmacodynamic activity of cefotaxime plus metronidazole with cefoxitin and ampicillin plus sulbactam.
Nightingale, CH; Quintiliani, R; Sullivan, MC; Sweeney, KR,
)
0.54
" Mean +/- SD values for cefoperazone steady-state volume of distribution (Vssd), elimination half-life (t1/2 beta), clearance (Cl), and area under the curve (AUC0-t) were 19."( Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.
Danziger, LH; Occhipinti, DJ; Piscitelli, SC; Resnick, DJ; Rodvold, KA, 1994
)
0.54
"To evaluate the pharmacodynamic antibacterial activity of ticarcillin-clavulanic acid (T-C) and ampicillin-sulbactam (A-S) combinations against reference bacterial strains in patients with end-stage renal disease maintained on long-term hemodialysis."( Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity.
Butler, SC; Hardin, TC; Jorgensen, JH; Ross, S; Wakeford, JH,
)
0.65
"This study evaluated the effects pregnancy had on pharmacokinetic parameters of ampicillin and sulbactam."( Pharmacokinetics of ampicillin and sulbactam in pregnancy.
Bawdon, R; Chamberlain, A; Larsen, B; Thomas, S; White, S, 1993
)
0.78
" Pharmacokinetic parameters were determined by fitting data (serum concentrations versus time) to a single-compartment model that provided elimination rate constants, beta-intercept (calculated concentration at 0 minutes), area under the time-versus-concentration curve, half-life of the drug, total body clearance, and volume of distribution."( Pharmacokinetics of ampicillin and sulbactam in pregnancy.
Bawdon, R; Chamberlain, A; Larsen, B; Thomas, S; White, S, 1993
)
0.56
"The pharmacokinetic behaviour of an ampicillin/sulbactam (2:1) combination was studied after intramuscular administration of a single dose (20 mg/kg body weight: 13."( Comparative pharmacokinetics of an ampicillin/sulbactam combination administered intramuscularly in lactating sheep and goats.
Cárceles, CM; Escudero, E; Espuny, A; Vicente, MS, 1996
)
0.81
"The pharmacokinetic behaviour of a combination of ampicillin and sulbactam (2:1) in six sheep and six goats after single intravenous doses of 20 mg kg body weight-1 (13."( Single-dose pharmacokinetics of ampicillin/sulbactam (2:1) combination after intravenous administration to sheep and goats.
Carceles, CM; Diaz, MS; Escudero, E; Espuny, A; Vicente, MS, 1996
)
0.79
"An in vitro pharmacokinetic model (IVPM) and a mouse model of lethal bacteremia were used to compare the pharmacodynamics of ampicillin-sulbactam when the two components were dosed simultaneously and in sequence against TEM-1-producing Escherichia coli."( Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.
Alexov, M; Lister, PD; Sanders, CC, 1996
)
0.81
"Some pharmacokinetic parameters of an ampicillin/sulbactam (2:1) combination were studied in six goats, after intravenous and intramuscular injection at a single dosage of 20 mg/kg bodyweight (13."( Some pharmacokinetic parameters of ampicillin/sulbactam combination after intravenous and intramuscular administration to goats.
Carceles, CM; Escudero, E; Espuny, A; Vicente, MS, 1996
)
0.81
"An in vitro pharmacokinetic model was used to study the pharmacodynamics of piperacillin-tazobactam and piperacillin-sulbactam against gram-negative bacilli producing plasmid-encoded beta-lactamases."( Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam.
Lister, PD; Prevan, AM; Sanders, CC, 1997
)
0.7
" Studies in animals, in vitro models, and pharmacokinetic considerations indicate that a change in the MIC breakpoint for ampicillin/sulbactam should be considered."( Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response.
Dudley, MN; Jones, RN, 1997
)
0.71
" The three beta-lactams were rapidly distributed into the different tissues and their pharmacokinetic profiles were found to be very similar."( Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery.
Dahmen, G; Göbel, C; Gotthardt, H; Gruber, H; Hille, E; Mallwitz, J; Pfaff, G; Wildfeuer, A,
)
0.41
" Both drugs had a similar pharmacokinetic behavior after intramuscular administration in sheep."( Pharmacokinetics of an ampicillin-sulbactam combination after intravenous and intramuscular administration to sheep.
Cárceles, CM; Escudero, E; Espuny, A; Vicente, S, 1999
)
0.58
" The objective of this article is to evaluate the pharmacokinetic properties of three commercially available beta-lactamase inhibitors."( Pharmacokinetic properties of beta-lactamase inhibitors.
de la Pena, A; Derendorf, H, 1999
)
0.3
"Based on published articles in the literature, the pharmacokinetic properties of the beta-lactamase inhibitors clavulanic acid, sulbactam and tazobactam are reviewed and compared."( Pharmacokinetic properties of beta-lactamase inhibitors.
de la Pena, A; Derendorf, H, 1999
)
0.51
"When choosing combinations of a beta-lactam antibiotic with a beta-lactamase inhibitor, it is important to make sure that the pharmacokinetic properties of drug and inhibitor are similar and remain similar under changing pathophysiological conditions."( Pharmacokinetic properties of beta-lactamase inhibitors.
de la Pena, A; Derendorf, H, 1999
)
0.3
" The AMX-SUL formulation evaluated in this study showed pharmacodynamic features that support clinical trials to assess its efficacy in the treatment of lower respiratory tract infections with a 12-h dosing interval regimen."( A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
Arenoso, HJ; Bantar, C; Blanco, M; Fernandez Canigia, L; Jasovich, A; Montoto, M; Nicola, F; Smayevsky, J; Soutric, J, 2000
)
0.54
" No changes in elimination half-life relative to a normal population occurred with cefuroxime, cefotiam, and ampicillin."( Pharmacokinetics of antibiotic prophylaxis in major orthopedic surgery and blood-saving techniques.
Dehne, MG; Hempelmann, G; Mühling, J; Nopens, H; Sablotzki, A, 2001
)
0.31
" The half-life of cefaperazone, although not statistically significantly different, was prolonged in all patients during the postoperative period."( Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
Agarwala, S; Gayowski, T; Mirani, A; Muder, RR; Venkataramanan, R, 2002
)
0.59
" The plasma concentration-time curves were analysed by compartmental pharmacokinetic and noncompartmental methods."( Pharmacokinetics of an ampicillin/sulbactam (2:1) combination in rabbits.
Cárceles, CM; Escudero, E; Serrano, JM; Vicente, MS, 2002
)
0.59
"The present multicenter study reports the results of a clinical trial, designed on the basis of a pharmacodynamic study published previously (Bantar et al."( Efficacy of amoxicillin-sulbactam, given twice-a-day, for the treatment of community-acquired pneumonia: a clinical trial based on a pharmacodynamic model.
Absi, R; Arenoso, H; Bantar, C; Bustos, JL; Curcio, D; Franco, D; Izaguirre, M; Jasovich, A; Larrateguy, L; Mastruzzo, M; Mobilia, L; Morera, G; Oliva, ME; Prieto, S; Soutric, J; Vesco, E, 2002
)
0.62
"We designed a 4-way crossover, ex-vivo pharmacodynamic study to compare the bactericidal rate of amoxicillin/sulbactam (AMX-SUL), azithromycin (AZM), doxycycline (DOX) and levofloxacin (LVX) against Streptococcus pneumoniae ATCC 49619."( An ex-vivo pharmacodynamic study comparing bactericidal activity of amoxicillin/sulbactam, azithromycin, doxycycline and levofloxacin against Streptococcus pneumoniae.
Arenoso, H; Bantar, C; Caruso, N; Fernández Canigia, L; Nicola, F; Soutric, J, 2004
)
0.76
" In this review we present the most relevant pharmacokinetic, pharmacodynamic and clinical information associated with its use."( Review of pharmacokinetic, pharmacodynamic and clinical studies with a modern combination of amoxicillin/sulbactam.
Arenoso, H; Bantar, C; Caruso, N; Casellas, JM; Farinati, A; Heguilén, R; Jasovich, A; Rodriguez, M; Soutric, J, 2006
)
0.55
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" the aim of this study was to identify the optimal dose and ratio between components of this formulation through an ex-vivo human pharmacodynamic model against Escherichia coli."( Intravenous amoxicillin-sulbactam against Escherichia coli: optimizing the dose, component ratio and infusion time using a human pharmacodynamic model.
Arenoso, HJ; Bantar, C; Berger, MA; Fernandez Canigia, L; Soutric, JL, 2009
)
0.66
" Thus, we sought to search the optimal dosing strategy for this formulation through an ex vivo pharmacodynamic human model against Acinetobacter baumanniii."( Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model.
Arenoso, HJ; Bantar, C; Berger, MA; Canigia, LF; Soutric, JL, 2009
)
0.62
" The method was successfully applied in a pharmacokinetic study of Sulperazon injection in six hospital-acquired pneumonia (HAP) patients."( Liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of cefoperazone and sulbactam in plasma and its application to a pharmacokinetic study.
Guo, B; Shi, Y; Wang, M; Yu, J; Zhang, J; Zhang, Y; Zhou, Y, 2010
)
0.57
"Twelve critically ill patients with anuric AKI being treated with ED were enrolled in a prospective, open-label, observational pharmacokinetic study."( Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis.
Broll, M; Burhenne, H; Burkhardt, O; Clajus, C; Hafer, C; Kaever, V; Kielstein, JT; Knitsch, W; Lorenzen, JM, 2012
)
0.66
" Plasma concentrations of ampicillin were simulated with the pharmacokinetic parameters obtained."( Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery.
Iguro, Y; Ikawa, K; Imoto, Y; Ishida, S; Matsumoto, K; Morikawa, N; Okano, Y; Shimodozono, Y; Takeda, Y; Watanabe, E; Yamada, K; Yamamoto, H; Yokoyama, Y, 2012
)
0.66
" Monte Carlo simulations were performed to determine the probability of attaining specific pharmacodynamic targets."( Pharmacodynamics modeling to optimize dosage regimens of sulbactam.
Aeinlang, N; Jaruratanasirikul, S; Jullangkoon, M; Wongpoowarak, W, 2013
)
0.64
" baumannii using an in vitro pharmacodynamic model."( In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Hagihara, M; Housman, ST; Kuti, JL; Nicolau, DP, 2013
)
0.62
"The aims of this study were to develop a population pharmacokinetic (PK) model of ampicillin and sulbactam, to identify patient characteristics influencing the PK, and to explore the relationship between dose regimen and degree of renal impairment with exposure and time above minimum inhibitory concentration (MIC)."( Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
Marshall, S; Muto, C; Shoji, S; Soto, E; Tomono, Y, 2014
)
0.88
" Drug exposure was expressed as the ratio of the area under the concentration-time curve for the free, unbound fraction of the drug to the MIC (fAUC/MIC) (VAN) or the time in a 24-h period that the drug concentration for the free, unbound fraction exceeded the MIC under steady-state pharmacokinetic conditions (fT(>MIC)) (SAM and TZP) and linked to the change in log10 CFU/thigh."( An optimized mouse thigh infection model for enterococci and its impact on antimicrobial pharmacodynamics.
Agudelo, M; Gonzalez, JM; Rodriguez, CA; Vesga, O; Zuluaga, AF, 2015
)
0.42
" The bile drug concentration-time data were processed by software to figure out the pharmacokinetic parameters such as maximum concentration (C(max)), peak time (T(max)), half-life time (T(1/2)), clearance (CL) and apparent volume of distribution (VD)."( [Experimental study on concentrations and pharmacokinetics of antibiotics in bile and evaluation of their microbicidal potential].
Lai, J; Li, S; Liang, L; Peng, B; Wang, Z; Zheng, J, 2014
)
0.4
"This study aimed to perform a pharmacokinetic (PK)-pharmacodynamic (PD) target attainment analysis of sulbactam against Acinetobacter baumannii in patients with impaired renal function."( Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
Ikawa, K; Matsumoto, K; Morikawa, N; Takeda, Y; Watanabe, E; Yokoyama, Y, 2015
)
0.86
" Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin."( Pharmacokinetics of Prophylactic Ampicillin-Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass.
Ikawa, K; Imoto, Y; Matsumoto, K; Morikawa, N; Takeda, Y; Watanabe, E; Yamamoto, H; Yokoyama, Y, 2015
)
0.68
" Major concern with FDC is the mutual interaction of its components that might influence their pharmacokinetic (PK) profile, requiring reassessing of whole formulation (adding cost and time)."( Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects.
Chaudhary, M; Sharma, VD; Singla, A; Taneja, M, 2016
)
0.67
" Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin and sulbactam."( The pharmacokinetics of ampicillin-sulbactam in anuric patients: dosing optimization for prophylaxis during cardiovascular surgery.
Ikawa, K; Imoto, Y; Matsumoto, K; Morikawa, N; Takeda, Y; Watanabe, E; Yamamoto, H; Yokoyama, Y, 2016
)
0.92
"We aimed to develop population pharmacokinetic (PK) models of ampicillin and sulbactam using pooled data analysis and to optimize dosing regimens of ampicillin-sulbactam (combination ratio of 2:1) in pediatric patients."( Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data.
Ikawa, K; Ishihara, N; Morikawa, N; Naora, K; Onita, T; Tamaki, H; Yano, T, 2022
)
1.22
" Based on these models, we estimated the probability of attaining a pharmacodynamic (PD) target [50% of time that free drug concentrations above the minimum inhibitory concentration, 50% fT > minimum inhibitory concentration (MIC)] against MIC90 [MIC that blocked the growth of 90% of the strains] of common bacteria in community-acquired pneumonia."( Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data.
Ikawa, K; Ishihara, N; Morikawa, N; Naora, K; Onita, T; Tamaki, H; Yano, T, 2022
)
0.99
"An adult physiologically based pharmacokinetic model was developed for meropenem, colistin, and sulbactam and scaled to pediatrics accounting for both renal and non-renal clearances."( Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Lv, Z; Oo, C; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S, 2022
)
1.18
" In a virtual pediatric population aged from 2 to < 18 years, the interpretive breakpoints were achieved in 85-90% of subjects for their targeted pharmacodynamic indices after administration of pediatric dosing regimens consisting of 30 mg/kg of meropenem, and 40 mg/kg of sulbactam three times daily as a 3-h or continuous infusion and 5 mg/kg/day of colistin base activity."( Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Lv, Z; Oo, C; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S, 2022
)
1.14
"The pharmacokinetic variability of ampicillin-sulbactam in adults has not been extensively described, particularly in patients with a reduced renal function (i."( Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients.
Abdul-Aziz, MH; Cotta, MO; Lukas, DL; Parker, S; Roberts, JA; Setiawan, E; Sosilya, H; Wallis, SC; Widjanarko, D, 2023
)
1.4
"The pharmacokinetic characteristics of sulbactam in critically ill patients with augmented renal clearance were investigated after the repeated administration of cefoperazone-sulbactam (3 g, q8, IV drip, combination ratio of 2 : 1)."( An HPLC-MS/MS method for determination of sulbactam in human plasma and its pharmacokinetic application in critically ill patients with augmented renal clearance.
Guo, N; Hu, S; Jiang, J; Leng, B; Shen, C; Zhang, L, 2023
)
1.44
" Pharmacokinetic parameters were determined by non-compartmental analysis (NCA) using Phoenix WinNonlin software."( An HPLC-MS/MS method for determination of sulbactam in human plasma and its pharmacokinetic application in critically ill patients with augmented renal clearance.
Guo, N; Hu, S; Jiang, J; Leng, B; Shen, C; Zhang, L, 2023
)
1.17

Compound-Compound Interactions

The in-vitro activity of cefsulodin combined with sulbactam, cefoxitin or cefotaxime was investigated against 32 strains of beta-lactamase-producing Bacteroides species. The activity of piperacillin/tazobactam and nafcillin alone and in combination with vancomycin was compared with van comycin monotherapy against MRSA in test-tube time-kill studies.

ExcerptReferenceRelevance
" Clavulanic acid at a concentration of 10 mg/l bound to PBP 2 by greater than 50% in all strains, and when combined with cefpirome, the density of PBP 2a was also reduced but not completely abolished."( Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.
Griggs, DJ; Piddock, LJ; Traynor, EA, 1992
)
0.28
"The minimal inhibitory concentrations of piperacillin (PIP) or cefotaxime (CTX) alone or in combination with tazobactam (TAZ) were determined against 168 anaerobes."( [Strict anaerobic bacteria: comparative study of various beta-lactam antibiotics in combination with tazobactam or sulbactam].
Dubreuil, L; Sedallian, A, 1991
)
0.49
"The in vitro antimicrobial activity of ticarcillin (TICAR), mezlocillin (MEZLO), piperacillin (PIPER), cefoperazone (CPZ), cefotaxime (CTX) and ceftazidime (CAZ), alone and in combination with 8 micrograms/ml of sulbactam (SULB), was studied by agar dilution against TICAR resistant strains isolated in 8 hospitals over a period of 3 months in 1989 (747 enterobacteria, 110 Ps."( [In vitro activity of beta-lactam antibiotics in combination with sulbactam against enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter. Results of a multicenter study].
Acar, JF; Denis, F; Drugeon, H; Fleurette, J; Kazmierczak, A; Siebor, E; Sirot, J; Soussy, CJ; Thabaut, A, 1991
)
0.7
"We compared the "in vitro" activity of imipenem with 14 beta-lactams, both alone and in combination with clavulanic acid, and sulbactam against 110 beta-lactamase-producing strains of Bacteroides fragilis."( Comparison of the activity of imipenem and beta-lactams combined with sulbactam and clavulanic acid in beta-lactamase-producing strains of Bacteroides fragilis.
Alados, JC; Castillo, AM; Liébana, J; Marín, A; Martín, MA; Piédrola, G, 1991
)
0.72
"An open multicenter study on inpatients of 12 german hospitals was performed to investigate efficacy and safety of sulbactam in combination with mezlocillin, piperacillin or cefotaxim in severe bacterial infections."( [Sulbactam in combination with mezlocillin, piperacillin or cefotaxime. Clinical and bacteriological results in the treatment of severe bacterial infections].
Heizmann, WR; Manncke, K; Sonntag, HG; Springsklee, M, 1991
)
1.4
"The in-vitro synergistic activity of tazobactam, a new beta-lactamase inhibitor, combined with piperacillin was tested against various beta-lactamase-producing strains."( Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.
Higashitani, F; Hyodo, A; Inoue, M; Ishida, N; Mitsuhashi, S, 1990
)
0.28
"We studied the efficacy of sulbactam, a beta-lactamase inhibitor, in combination with ceftriaxone in vitro and in experimental endocarditis due to an Escherichia coli strain producing an extended-spectrum beta-lactamase most similar to SHV-2, a new mechanism of resistance to broad-spectrum cephalosporins among members of the family Enterobacteriaceae."( Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase.
Buré, A; Carbon, C; Caron, F; Fantin, B; Mohler, J; Pangon, B; Philippon, A; Potel, G; Vallée, E; Vallois, JM, 1990
)
0.95
" In comparison with the antibiotic alone, the most marked reductions in the number of resistant strains on combination with sulbactam were as follows (the percentage of reduction is shown in brackets): for SUL + AMP and Acine-tobacter spp."( In vitro activity against clinically important gram-positive and gram-negative bacteria of sulbactam, alone and in combination with ampicillin, cefotaxime, mezlocillin, and piperacillin.
Schmalreck, AF; Wildfeuer, A, 1990
)
0.71
"We studied the sensitivity of 160 strains of Bacteroides fragilis (74 beta-lactamase-positive and 86 beta-lactamase-negative) to four third-generation cephalosporins, alone as well as in combination with clavulanic acid and Sulbactam."( Increase in the activity of third-generation cephalosporins in combination with clavulanic acid and Sulbactam against Bacteroides fragilis.
Castillo, AM; Gutierrez, J; Liebana, J; Martín, MA; Mesa, P; Piedrola, G, 1990
)
0.68
" Thus the physicochemical and pharmacological properties of sulbactam apparently permit flexible dosage in combination with different penicillins or cephalosporins and sulbactam can be administered as non-fixed combination in the clinical treatment of bacterial infections."( Studies on the synergism of sulbactam and beta-lactam antibiotics under in vitro conditions and in healthy volunteers after intravenous administration. Antibacterial activity in vitro, compatibility and pharmacokinetics of the drugs in combination.
Eibel, G; Pfaff, G; Räder, K; Schmalreck, A; Wildfeuer, A, 1989
)
0.81
" Combinations of methicillin and penicillin G with sulbactam also showed synergistic effects against 50 and 68% of the strains, respectively, while cefotiam, moxalactam, flomoxef, and cefmetazole in combination with sulbactam showed such effects against only 40% or fewer."( In vitro effects of beta-lactams combined with beta-lactamase inhibitors against methicillin-resistant Staphylococcus aureus.
Arai, S; Hayashi, S; Kobayashi, S; Sakaguchi, T, 1989
)
0.53
"The in vitro synergistic activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam, combined with ampicillin, ticarcillin, mezlocillin, azlocillin, piperacillin, and apalcillin, were determined against 34 strains of members of the Enterobacteriaceae family, Pseudomonas aeruginosa, Aeromonas hydrophila, and Haemophilus influenzae with characterized plasmid or chromosomal beta-lactamases or both."( Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.
Aronoff, SC; Jacobs, MR; Johenning, S; Shlaes, DM; Yamabe, S, 1986
)
0.72
"The in-vitro synergistic activity of YTR 830, a new beta-lactamase inhibitor, combined with four extended-spectrum penicillins (ticarcillin, piperacillin, mezlocillin and apalcillin) against ticarcillin-resistant clinical isolates of Gram-negative enteric bacilli was compared with that of clavulanate and sulbactam."( Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate and sulbactam combined with extended-spectrum penicillins against ticarcillin-resistant Enterobacteriaceae and pseudomonads.
Aronoff, SC; Jacobs, MR; Johenning, S; Yamabe, S, 1986
)
0.67
"The in vitro activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with six beta-lactams against 88 beta-lactamase-producing anaerobes were determined."( Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes.
Appelbaum, PC; Jacobs, MR; Spangler, SK; Yamabe, S, 1986
)
0.73
"The in-vitro activity of a beta-lactamase inhibitor (clavulanic acid, sulbactam, BL-P2013 or BL-P2090) in combination with ampicillin against 13 isolates of Mycobacterium tuberculosis was determined by broth dilution."( Comparison of four beta-lactamase inhibitors in combination with ampicillin against Mycobacterium tuberculosis.
Cynamon, MH; Sorg, TB, 1987
)
0.51
"Several in vitro parameters of sulbactam combined with ampicillin (Sbt/Amp) were studied in order to evaluate and compare its microbiological properties with those of beta-lactamase stable beta-lactams (ceftriaxone, cefamandole, cefoxitin)."( Microbiological properties of sulbactam combined with ampicillin.
Barba, D; Esposito, S; Galante, D; Ruffilli, MP, 1987
)
0.85
" Combined with amoxicillin, YTR 830 is a potentially useful agent for therapy of many bacterial infections."( Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.
Aronoff, SC; Jacobs, MR; Johenning, S; Yamabe, S, 1984
)
0.49
"The beta-lactamase inhibitors clavulanic acid and sulbactam were combined with mecillinam."( Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.
Neu, HC, 1982
)
0.73
"The in-vitro activity of cefsulodin combined with sulbactam, cefoxitin or cefotaxime was investigated against 32 strains of beta-lactamase-producing Bacteroides species."( Synergistic activity of cefsulodin combined with cefoxitin and sulbactam against Bacteroides species.
Fu, KP; Kimble, EF; Konopka, EA; Zoganas, H, 1984
)
0.76
"The activity of penicillin, alone and in combination with sulbactam, against a heterogeneously methicillin-resistant, penicillinase-producing clinical isolate of Staphylococcus aureus and its penicillinase-negative derivative was investigated in vitro and in a rabbit experimental endocarditis model."( Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Carbon, C; Castéla-Papin, N; Drugeon, H; Fantin, B; Farinotti, R; Pierre, J; Saint-Julien, L, 1996
)
0.76
"The purpose of this prospective randomized study was to compare the efficacy and safety of imipenem and cefoperazone-sulbactam combined with vancomycin for the treatment of fever in neutropenic cancer patients."( Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients.
Abi-Said, D; Bodey, G; Raad, I; Rolston, K; Whimbey, E, 1996
)
0.81
"The activity of piperacillin/tazobactam, ampicillin/sulbactam, imipenem and nafcillin alone and in combination with vancomycin was compared with vancomycin monotherapy against MRSA in test-tube time-kill studies and in infected fibrin clots."( An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin
Palmer, SM; Rybak, MJ, 1997
)
0.79
"In the treatment of severe infections complicated to blood dyscrasia, the efficacy and usefulness of fosfomycin (FOM) in combination with sulbactam (SBT)/cefoperazone (CPZ) were compared between patients receiving FOM in the first followed by SBT/CPZ (Group A) and those receiving both drugs simultaneously (Group B)."( [Clinical efficacy of fosfomycin in combination with sulbactam/cefoperazone in the treatment of severe infections complicated to blood dyscrasia. Working Group of Kanto Combination Therapy for FOM + SBT/CPZ].
Ann, E; Bessho, M; Dan, K; Egashira, M; Fukuda, M; Hirai, H; Hirasawa, A; Hirashima, K; Hoshino, T; Hosoya, N; Ikeda, Y; Karasawa, M; Kawai, N; Kitamura, K; Kizaki, M; Miura, Y; Miyazawa, K; Nagasu, M; Naruse, T; Noguchi, M; Ohmine, K; Oshimi, K; Sugai, M; Takagi, S; Toyama, K, 1998
)
0.75
"This in vitro study evaluated the activities of vancomycin, LY333328, and teicoplanin alone and in combination with gentamicin, rifampin, and RP59500 against Staphylococcus aureus isolates with intermediate susceptibilities to vancomycin."( Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by
Aeschlimann, JR; Hershberger, E; Moldovan, T; Rybak, MJ, 1999
)
0.53
"The in vitro activity of the beta-lactamase inhibitor sulbactam combined with cefuroxime, cefotaxime or ceftazidime in the ratio of 1:1 was studied against ceftazidime- or cefuroxime-resistant Gram-negative rods and Staphylococcus aureus."( The in vitro activity of sulbactam combined with third generation cephalosporins against third generation cephalosporin-resistant bacteria.
Li, JT; Zhang, YL, 2001
)
0.86
"The aim of this study was to assess the in vitro activity of cefepime combined with sulbactam against carbapenem-resistant clinical isolates of Acinetobacter spp."( In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp.
Chai, D; Li, Z; Pei, F; Tong, W; Wang, R, 2006
)
0.82
" The use of bectalactamases inhibitors combined with betalactam antibiotics allows the inactivation of certain betalactamases produced by Gram positive, Gram negative and anaerobic organisms, and even by mycobacteria."( [Betalactam antibiotics combined with bectalactamases inhibitors. Amoxicillin-sulbactam].
Barcelona, L; Marín, M; Stamboulian, D, 2008
)
0.57
"We investigated in vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against Gram-negative bacilli."( In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
Kuo, HY; Lin, ML; Liu, CY; Wang, FD; Yen, YF, 2009
)
0.35
"We report a case of postsurgical meningitis caused by multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin."( Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin/sulbactam combined with rifampicin and fosfomycin.
Clec'h, C; Cohen, Y; Jauréguy, F; Mellon, G; Picard, B, 2012
)
0.78
"The aim of this study was to investigate the in vitro activity of minocycline combined with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii (CRAB)."( In vitro activity of minocycline alone and in combination with cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii.
Mao, Y; Pei, G; Sun, Y, 2012
)
0.82
" The purpose of this study was to investigate the clinical outcomes of patients with healthcare-associated infections (HAIs) caused by MDRAB who were treated with imipenem/cilastatin and sulbactam, and TG alone or in combination with other antibiotics."( Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.
Hsueh, PR; Lee, YT; Tsao, SM, 2013
)
0.58
" Moreover, tigecycline in combination with cefoperazone-sulbactam appeared to be more effective than tigecycline in combination with sulbactam against XDRAB."( In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.
Bai, Y; Di, X; Liu, B; Liu, Y; Wang, J; Wang, R; Zhang, X, 2015
)
0.9
"Neither the administration of colistin alone nor colistin combined with either sulbactam or carbapenem had any noticeable advantage in the treatment of VAP in terms of clinical response, microbiological response, nephrotoxicity, length of hospitalization, and mortality."( Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia.
Acikgoz, ZC; Guner, R; Guven, T; Izdes, S; Kocak Tufan, Z; Tasyaran, MA; Yilmaz, GR, 2015
)
0.93
"2%) of the 121 MDR-TB strains were subjected to a synergistic effect when the drug was combined with sulbactam, tazobactam, or clavulanate, respectively."( In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Lu, J; Pang, Y; Wang, Y; Zhang, D, 2016
)
0.65
"The present study evaluates the synergistic effect of sulbactam/tazobactam in combination with meropenem or colistin against multidrug resistant (MDR) Acinetobacter baumannii isolated from hospitalized patients from a tertiary care hospital in Saudi Arabia."( A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.
Alyousef, AA; Alzahrani, AJ; Krishnappa, LG; Marie, MA; Mubaraki, MA, 2015
)
0.92
" Using a murine thigh-infection model, we examined the in vivo efficacy of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains."( Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model.
Cong, Y; Fan, B; Guan, J; Wang, X, 2016
)
0.84
" In this study, the activity of colistin (COL) as monotherapy and in combination with other antibiotics against Acinetobacter baumannii in vitro was investigated."( In vitro and in vivo assessment of the antibacterial activity of colistin alone and in combination with other antibiotics against Acinetobacter baumannii and Escherichia coli.
Fu, L; Li, H; Li, X; Liu, J; Luo, S; Wan, Z; Wang, Y; Wu, X; Xie, X; Zhao, Z, 2020
)
0.56
" SIGNIFICANCE AND IMPACT OF THE STUDY: Drug combination is an effective approach for the treatment of resistant bacterial infection."( In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Li, X; Lu, C; Sun, S; Wang, D; Wang, Y, 2020
)
0.56
"The aim of this study was to compare the effectiveness of cefoperazone-sulbactam alone and combined with tigecycline in the treatment of multi-drug resistant acinetobacter baumannii pulmonary infection."( Effectiveness of Cefoperazone-sulbactam alone and Combined with Tigecycline in the Treatment of Multi-drug Resistant Acinetobacter Baumannii Pulmonary Infection.
Chen, L; Deng, Y; Lv, Q; Ruan, J; Zhu, X, 2020
)
1.08
" Also, the mutant prevention concentration (MPC)s of cefepime alone or in combination with sulbactam was determined."( In Vitro Synergistic Effect and Mutant Prevention Concentrations of Cefepime Alone or in Combination with Sulbactam Against OXA-48-positive Klebsiella pneumoniae Isolates.
Mataracı-Kara, E; Özbek-Çelik, B; Yılmaz, M, 2020
)
0.99
" She was administered cefoperazone and sulbactam sodium + metronidazole sodium chloride combined with morphine hydrochloride perioperatively, which caused a rash as an adverse side effect."( A case report of rash induced by cefoperazone sodium and sulbactam sodium plus metronidazole sodium chloride combined with morphine hydrochloride.
Huang, J; Jiang, C; Liu, Z; Zhu, X, 2020
)
1.07
"Reducing the time of invasive catheter placement and mechanical ventilation in patients in the intensive care unit (ICU), antimicrobial treatment, combined with tigecycline and sulbactam, might help reduce the mortality rate in patients with severe MDR-AB hospital-acquired pneumonia."( Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia.
Chen, L; Deng, Y; Huang, X; Yang, Y; Yu, H; Yue, M, 2022
)
2.36
"Evaluate the in vivo efficacy and resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam and meropenem using human-simulated regimens (HSR) in the murine infection model."( In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii.
Echols, R; Gill, CM; Longshaw, C; Nicolau, DP; Santini, D; Takemura, M; Yamano, Y, 2023
)
1.33
" When combined with sulbactam, durlobactam effectively restores the susceptibility of resistant isolates through β-lactamase inhibition."( The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex.
Bhavnani, SM; O'Donnell, JP, 2023
)
1.46

Bioavailability

The absolute bioavailability of the intraperitoneal dose was 61% for cefoperazone and 70% for sulbactam. First-pass hydrolysis of this prodrug liberates equimolar proportions of sulbacts in plasma, saliva and urine.

ExcerptReferenceRelevance
"Oral bioavailability of ampicillin when bound to sulbactam (sultamicillin) compared with ampicillin alone and that of amoxycillin with a ligand of clavulanic acid versus amoxycillin alone were assessed in 16 healthy subjects using an open label, multiple crossover study."( Oral bioavailability of ampicillin and amoxycillin alone and bound in fixed proportions to sulbactam and clavulanic acid.
Costermans, J; Desager, JP; Harvengt, C; Van Nieuwenhuyze, Y,
)
0.61
" We conclude that until bioavailability studies are performed these three antibiotics should not be coadministered with nicardipine HCl."( The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
Alicea, M; Colucci, RD; Greenstein, R; Halpern, NA, 1989
)
0.28
" Sulbactam is poorly absorbed after oral administration and sulbactam/ampicillin is therefore administered parenterally, although another linked sulbactam-ampicillin compound, sultamicillin, has been developed which is well absorbed after oral administration."( Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
Brogden, RN; Campoli-Richards, DM, 1987
)
2.63
" Test results showed that the addition of sulbactam significantly increases the bioavailability of oral ampicillin when the 2 drugs are administered in the form of the prodrug sultamicillin."( Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers.
Bruckner, G; Hampel, B; Koeppe, P; Lode, H, 1988
)
0.82
" (area under the burn blister fluid concentration of drug-time curve between 0 and 8 hours after injection), absorption rate constant (ka) and therapeutic AUC (AUC where drug concentrations were above minimum effective concentration) of CPZ were calculated to be 194."( [Transfer of injected sulbactam/cefoperazone into burn blister fluid].
Aoyama, H; Izawa, Y; Okuda, J; Sugiyama, H; Tada, M, 1988
)
0.59
" The absolute bioavailability of the intraperitoneal dose was 61% for cefoperazone and 70% for sulbactam."( Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.
Craig, WA; Johnson, CA; Leggett, JE; Reitberg, DP; Whall, TJ; Zimmerman, SW, 1988
)
0.74
" First-pass hydrolysis of this prodrug liberates equimolar proportions of sulbactam in plasma, saliva and urine is described and was used to determine the absolute bioavailability of sulbactam and ampicillin from sultamicillin in six normal male volunteers who each received a single 750 mg oral dose of sultamicillin or an iv dose of the equivalent amounts of ampicillin (441 mg) and sulbactam (294 mg)."( Pharmacokinetics and bioavailability of sultamicillin estimated by high performance liquid chromatography.
Bradbrook, ID; Cox, DA; Lees, LJ; Morrison, PJ; ROgers, HJ; Spector, RG, 1983
)
0.5
"5 times greater total bioavailability for ampicillin and sulbactam than when each was used individually."( Pharmacokinetics of sultamicillin in mice, rats, and dogs.
English, AR; Girard, D; Haskell, SL, 1984
)
0.51
" The bioavailability after intramuscular injection was high and similar for both drugs (98."( Some pharmacokinetic parameters of ampicillin/sulbactam combination after intravenous and intramuscular administration to goats.
Carceles, CM; Escudero, E; Espuny, A; Vicente, MS, 1996
)
0.55
" The bioavailability after intramuscular injection was high and similar in both drugs (72."( Pharmacokinetics of an ampicillin-sulbactam combination after intravenous and intramuscular administration to sheep.
Cárceles, CM; Escudero, E; Espuny, A; Vicente, S, 1999
)
0.58
" The bioavailability after intramuscular injection was high and similar in both drugs (73."( Pharmacokinetics of an ampicillin/sulbactam (2:1) combination in rabbits.
Cárceles, CM; Escudero, E; Serrano, JM; Vicente, MS, 2002
)
0.59
" The aim of the present studies, performed in two different groups of volunteers, was to compare the bioavailability of 750 mg sultamicillin tablets (Duobaktam 750 mg tablets, study 1) and sultamicillin 250 mg/5mL suspensions (Duobaktam 250 mg/5mL, study 2)."( Effect of the formulation on the bioequivalence of sultamicillin: tablets and suspension.
Alpan, RS; Erenmemisoglu, A; Koytchev, R; Kunter, U; Ozalp, Y, 2004
)
0.32
"To investigate the disposition kinetics of ampicillin and sulbactam after IV and IM administration of an ampicillin-sulbactam (2:1) preparation and determine the bioavailability of the combined preparation after IM administration in turkeys."( Pharmacokinetics of a combination preparation of ampicillin and sulbactam in turkeys.
Cárceles, CM; Escudero, E; Espuny, A; Fernández-Varón, E; Marín, P, 2004
)
0.81
" Bioavailability after IM injection was 58."( Pharmacokinetics of a combination preparation of ampicillin and sulbactam in turkeys.
Cárceles, CM; Escudero, E; Espuny, A; Fernández-Varón, E; Marín, P, 2004
)
0.56
" The present study was performed to investigate the relative bioavailability and to assess the bioequivalence of two different sultamicillin suspensions (Devasid 250 mg/5 ml as test preparation and 375 mg/7."( Bioequivalence study of sultamicillin suspensions.
Arnold, P; Erenmemişoğlu, A; Hincal, AA; Kanzik, I; Martin, W; Sailer, R; Tamur, U, 2007
)
0.34
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The described dosing regimen for ampicillin/sulbactam is safe with respect to the defined MIC breakpoints. There was no significant accumulation using a twice-daily dosage of 2 g/1 g ampicILLON/SULBACTam. The disposition of cefoperazone/sulpacam is altered, but not likely to warrant a dosage reduction.

ExcerptRelevanceReference
" The daily dosage of Unasyn was 3-12 g/die administered in three to four divided doses, and was determined by the severity of infection, the antibiotic susceptibility of the causative organism(s) and the condition of the patient."( [Sulbactam-ampicillin in surgery. Our experience].
Casiraghi, S; Caspani, P; Germiniani, R; Pace, M; Trabucchi, E, 1992
)
1.19
" All antibiotics were given by intravenous bolus injection in a number of dosing regimens."( Use of ampicillin-sulbactam for treatment of experimental meningitis caused by a beta-lactamase-producing strain of Escherichia coli K-1.
Fournier, MA; Guerra-Romero, L; Kennedy, SL; Täuber, MG; Tureen, JH, 1991
)
0.62
"A total of 124 patients with lower respiratory tract (44) or urinary tract infections (80) were enrolled in an open, multicenter study to evaluate the efficacy and tolerability of sulbactam/ampicillin, administered at the dosage of 3 g/die by intramuscular route."( Clinical results of a multicenter study with sulbactam/ampicillin for the treatment of patients with lower respiratory and urinary tract infections.
Chiodo, F; De Simone, C; Delia, S; Gargiulo, M; Paoloni, M; Pastore, G; Scalise, G; Sorice, F; Tonietti, G; Zanussi, C, 1991
)
0.73
" It was concluded that both drugs could be administered concomitantly without any dosage adjustment of theophylline."( Influence of sulbactam plus ampicillin on theophylline clearance.
Caputi, M; Cazzola, M; Girbino, G; Guidetti, E; Mattina, R; Santangelo, G, 1991
)
0.65
" The dosage was considered appropriate in 88% of the patients."( Use of ampicillin-sulbactam before and after formulary inclusion.
Koch, KE; Taylor, MR, 1991
)
0.62
" The treatment was continued for at least 7 days for 24 patients at the dosage of 3 g sulbactam/ampicillin twice daily, for a further 24 patients at the dosage of 6 g piperacillin twice daily and for two patients at the dosage of 8 g piperacillin twice daily."( Sulbactam/ampicillin combination in the treatment of acute and chronic lower respiratory infections.
Bisetti, A; Grassi, L; Putti, P; Scacciacillani, E, 1991
)
1.95
" In vivo, sulbactam given at 200 mg/kg of body weight every 12 h, a dosage higher than that previously reported to be effective against rabbit endocarditis caused by other microorganisms, was not sufficient to restore the complete activity of ceftriaxone given at 30 mg/kg once daily for 4 days."( Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.
Bure, A; Carbon, C; Caron, F; Gutmann, L; Pangon, B; Pechinot, A; Vallois, JM, 1990
)
1.06
" The reported method was employed to evaluate the samples of sera of volunteers after intravenous administration of the dosage form sulbaktam-ampicillin (VUFB) and the foreign pharmaceutical preparation Unasyn (Pfizer)."( [Determination of sulbactam in human serum using capillary isotachophoresis].
Dohnal, J; Holá, V; Jelínek, I; Krejcírová, H; Rejholec, V; Roubal, Z, 1990
)
0.61
" The mean peak ampicillin and sulbactam serum concentrations following intravenous dosing were 170."( Ampicillin and sulbactam pharmacokinetics and pharmacodynamics in continuous ambulatory peritoneal dialysis (CAPD).
Blackwell, BG; Craig, WA; Johnson, CA; Leggett, JE; Zimmerman, SW, 1990
)
0.92
" Carboxyl-terminated double esters have several potential advantages over their nonionizable lipophilic counterparts, including water solubility, crystallinity, choice of salts for dosage forms, and formation of innocuous byproducts on hydrolysis."( Orally effective acid prodrugs of the beta-lactamase inhibitor sulbactam.
English, AR; Girard, D; Jasys, VJ; Kellogg, MS; Martingano, RJ, 1990
)
0.52
" For combined ampicillin/sulbactam dosage forms the ratios of 1:1 to 2:1 should be recommended."( [Kinetics of the antibacterial effect of ampicillin and sulbactam combinations in dynamic and static conditions].
Chernykh, VM; Firsov, AA; Nazarov, AD; Samoĭlova, LN; Treskina, OS, 1989
)
0.83
" No adverse side-effects were reported and dosage adjustment was not required in the elderly."( Clinical efficacy of sulbactam/ampicillin in the treatment of moderately severe bacterial infections.
Boey, ML; Feng, PH; Fong, KY; Howe, HS, 1989
)
0.6
" Several factors support such usage: 1) the superiority of sultamicillin compared with the ampicillin commercial dosage form as a delivery system for ampicillin; 2) the possible occurrence at the infection site of beta-lactamase-producing organisms, not themselves pathogens, which nevertheless impair the activity of the beta-lactam antibiotic against sensitive pathogens; 3) the complementary binding of penicillin-binding proteins by ampicillin and sulbactam in ampicillin-sensitive organisms; 4) the lack of resistance development following repeated exposure of strains sensitive to sulbactam/ampicillin suggested by in vitro studies; and 5) the inability of sulbactam to induce beta-lactamase production."( Worldwide clinical experience with sultamicillin.
Gilbert, GS; Knirsch, AK; Noguchi, Y; Pitts, NE, 1989
)
0.44
" The most common dosage regimen was 375 mg three times daily."( Sultamicillin in the treatment of urinary tract infections.
Kawada, Y, 1989
)
0.28
" Further studies in larger groups of patients are needed to clarify the therapeutic efficacy and safety of sultamicillin in comparison with other antibacterial regimens, and to determine the optimum single dosage for the treatment of gonorrhoea."( Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Campoli-Richards, DM; Friedel, HA; Goa, KL, 1989
)
0.28
" SBT/ABPC was administered to 14 patients with bronchopneumonia, 4 patients with tonsillitis, a patient each with acute upper respiratory infection, with submandibular lymphadenitis, with phlegmon, with enterocolitis, with pyelonephritis and with cystitis at a daily dosage of 88."( [Clinical evaluation of sulbactam/ampicillin in children].
Ito, M; Ito, S; Mayumi, M; Mikawa, H, 1989
)
0.58
" The dosage used was 101."( [Pharmacokinetic, bacteriological and clinical studies of sulbactam/ampicillin in pediatric patients].
Aramaki, M; Fujimoto, T; Koga, T; Motohiro, T; Oda, K; Sakamoto, H; Sakata, Y; Shimada, Y; Tanaka, K; Yamashita, F, 1989
)
0.52
" Sulbactam/ampicillin was given by intravenous bolus in a dosage range of 75-450 mg/kg/day in four divided doses for variable periods of time depending on the type and severity of the infection."( Intravenous sulbactam/ampicillin in the treatment of pediatric infections.
Chen, CM; Chu, ML; Hsu, CY; Huang, LM; Lee, CY; Lee, MJ; Lin, TY,
)
1.42
" dosage regimen would be appropriate."( [Clinical evaluation of sulbactam/ampicillin in the pediatric infections].
Abe, T; Arimasu, O; Fujii, R; Hiruma, F; Mashiko, J; Meguro, H; Nagao, Y; Okamoto, Y; Shiraishi, H; Sugamata, K, 1989
)
0.58
" Twenty pediatric patients with infection were treated with SBT/ABPC and an intravenous dosage of 27."( [Bacteriological, pharmacokinetic and clinical studies of sulbactam/ampicillin in the pediatric field].
Haruta, T; Hashimoto, H; Kobayashi, Y; Kuroki, S; Okura, K; Yamaoka, K; Yoshioka, N, 1989
)
0.52
" Thus the physicochemical and pharmacological properties of sulbactam apparently permit flexible dosage in combination with different penicillins or cephalosporins and sulbactam can be administered as non-fixed combination in the clinical treatment of bacterial infections."( Studies on the synergism of sulbactam and beta-lactam antibiotics under in vitro conditions and in healthy volunteers after intravenous administration. Antibacterial activity in vitro, compatibility and pharmacokinetics of the drugs in combination.
Eibel, G; Pfaff, G; Räder, K; Schmalreck, A; Wildfeuer, A, 1989
)
0.81
" Therefore, sulbactam should predictably increase the antimicrobial spectrum and clinical effectiveness of cefoperazone against nosocomial and other pathogens such as the plasmid-containing enteric bacilli, Bacteroides species and Acinetobacter species, and possibly provide the opportunity to reduce dosage schedules for infecting species already susceptible to cefoperazone alone."( In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies.
Barry, AL; Jones, RN; Thornsberry, C; Wilson, HW, 1985
)
0.9
"5 or 25 mg/kg were infused over 3 min, and in previously healthy children, mean peak plasma concentrations 5 min after dosing were 71 and 163 micrograms/ml, respectively."( Single-dose pharmacokinetics of intravenous sulbactam in pediatric patients.
Guenin, K; Schaad, UB; Straehl, P,
)
0.39
" The aims were to determine an appropriate dosage regimen and to study the pharmacokinetics."( Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn.
Cockburn, F; McAllister, TA; Sutton, AM; Turner, TL,
)
0.43
" Sulbactam/ampicillin was administered im or iv at a dosage of 3-9 g/day depending on the site and severity of the infection."( Clinical efficacy and safety of sulbactam/ampicillin in patients suffering from chronic liver disease.
Barba, D; Esposito, S; Galante, D; Ruffilli, MP, 1987
)
1.47
" SBTPC fine granules were administered orally to 1 patient with bronchitis, 9 patients with bronchopneumonia, 7 patients with tonsillitis, 4 patients with scarlet fever, 1 patient each with pharyngitis, otitis media, purulent parotitis, and urinary tract infection and 6 patients with skin and soft tissue infections at daily dosage levels of 26."( [Clinical evaluation of sultamicillin fine granules in pediatric patients].
Ito, S; Mayumi, M; Mikawa, H, 1988
)
0.27
" The patients included 9 boys and 10 girls from 11 months to 13 years old and they were given orally a dosage of 15."( [Clinical study of sultamicillin fine granules].
Kawakami, K; Okada, K; Takeda, E, 1988
)
0.27
" The dosage was 10-30 mg/kg daily."( [Efficacy of sultamicillin fine granules in pyoderma, particularly in impetigo contagiosa].
Inoue, Y; Kawashima, T; Tokuda, Y, 1988
)
0.27
" Only intraperitoneal dosing provided peak inhibitory and bactericidal titers in dialysate for all organisms tested."( Pharmacokinetics and pharmacodynamics of cefoperazone-sulbactam in patients on continuous ambulatory peritoneal dialysis.
Craig, WA; Johnson, CA; Leggett, JE; Reitberg, DP; Whall, TJ; Zimmerman, SW, 1988
)
0.52
" Serial blood and urine samples were collected from time zero to 12 h after dosing in normal subjects and from 0 to 72 h in renal patients."( Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
Marble, DA; Reitberg, DP; Schentag, JJ; Schultz, RW; Whall, TJ, 1988
)
0.53
" Two dosage schedules were investigated, both resulting in the same total daily dosage (1500 mg sultamicillin)."( Sultamicillin (CP-49, 952): evaluation of two dosage schedules in urinary infection.
Ball, AP; Fox, C; Ghosh, D, 1984
)
0.27
" SBT/CPZ was given to total 43 cases at a mean daily dosage of 80."( [Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field].
Fujimoto, T; Ishimoto, K; Koga, T; Motohiro, T; Nishiyama, T; Sakata, Y; Shimada, Y; Tanaka, K; Tominaga, K; Tomita, N, 1984
)
0.54
" Based on these results, SBT/CPZ is considered to be a highly effective antibiotic with clinical efficacy in obstetric and gynecological infections in the daily dosage of 2 g given in two divided doses."( [Experience with sulbactam/cefoperazone in the field of obstetrics and gynecology].
Hirai, S; Iida, S; Kohara, T; Matsui, Y; Noda, M, 1984
)
0.61
" One patient in each dosage group discontinued the medication because of severe diarrhoea."( Clinical, bacteriological and pharmacokinetic results from an open trial of sultamicillin in patients with acute exacerbations of chronic bronchitis.
Davies, BI; Maesen, FP; van Noord, JA, 1984
)
0.27
" Serum levels of cefoperazone-sulbactam measured at one and three hours after dosing were consistent with earlier findings in normal volunteers."( Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra-abdominal infections.
Bowen, K; Cayavec, P; Danko, LS; Greenberg, RN; Johnson, SB; Kearney, PA; Montazemi, R; Strodel, WE, 1994
)
0.86
" The disposition of cefoperazone/sulbactam is altered in this group of patients; however, these changes are not likely to warrant a dosage reduction."( Steady-state pharmacokinetics of cefoperazone and sulbactam in patients with acute appendicitis.
Danziger, LH; Occhipinti, DJ; Piscitelli, SC; Resnick, DJ; Rodvold, KA, 1994
)
0.82
"Increasing the dosing interval for T-C in patients with end-stage renal disease may lead to periods of insufficient clavulanic acid to protect ticarcillin from beta-lactamase degradation."( Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity.
Butler, SC; Hardin, TC; Jorgensen, JH; Ross, S; Wakeford, JH,
)
0.43
"Because pregnancy is associated with more rapid elimination of beta-lactam drugs, physicians treating infections in pregnant or newly parturient women should consider using shorter intervals between antibiotic doses when a range of dosage intervals is under consideration."( Pharmacokinetics of ampicillin and sulbactam in pregnancy.
Bawdon, R; Chamberlain, A; Larsen, B; Thomas, S; White, S, 1993
)
0.56
" Against the borderline oxacillin-susceptible strain BOSSA-1, increasing the sulbactam dosage from 500 to 2,000 mg/kg/day while maintaining a fixed dose of ampicillin (1,000 mg/kg/day) by continuous infusion resulted in lower bacterial counts (4."( Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus.
Eliopoulos, GM; Moellering, RC; Pefanis, A; Thauvin-Eliopoulos, C, 1993
)
0.83
" It was concluded that the similarity in the disposition and elimination of both drugs in sheep and goats indicated that the combination preparation could be administered at the same dosing rate in both species."( Comparative pharmacokinetics of an ampicillin/sulbactam combination administered intramuscularly in lactating sheep and goats.
Cárceles, CM; Escudero, E; Espuny, A; Vicente, MS, 1996
)
0.55
"An in vitro pharmacokinetic model (IVPM) and a mouse model of lethal bacteremia were used to compare the pharmacodynamics of ampicillin-sulbactam when the two components were dosed simultaneously and in sequence against TEM-1-producing Escherichia coli."( Efficacy of ampicillin-sulbactam is not dependent upon maintenance of a critical ratio between components: sulbactam pharmacokinetics in pharmacodynamic interactions.
Alexov, M; Lister, PD; Sanders, CC, 1996
)
0.81
"Some pharmacokinetic parameters of an ampicillin/sulbactam (2:1) combination were studied in six goats, after intravenous and intramuscular injection at a single dosage of 20 mg/kg bodyweight (13."( Some pharmacokinetic parameters of ampicillin/sulbactam combination after intravenous and intramuscular administration to goats.
Carceles, CM; Escudero, E; Espuny, A; Vicente, MS, 1996
)
0.81
" Serum bactericidal titers were determined and used to calculate the duration of measurable bactericidal activity over the dosing interval of each of the regimens against two clinical isolates of Bacillus fragilis, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa."( Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa.
Klepser, ME; Marangos, MN; Nicolau, DP; Nightingale, CH; Quintiliani, R; Zhu, Z, 1997
)
0.51
"In this study, we investigated the pharmacokinetics of the acylureidopenicillin mezlocillin and the beta-lactamase inhibitor sulbactam during CVVHD and deduced dosage recommendations from the kinetic parameters with the goal of maintaining trough levels of above 10 mg."( Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure.
Drewelow, B; Ehmcke, H; Hickstein, H; Rohde, B; Werner, U, 1997
)
0.78
"Due to high hepatobiliary clearance of mezlocillin, dosage adjustments in patients with acute renal failure, treated by CVVHD, are needed only with concurrent impaired liver function."( Pharmacokinetics of mezlocillin and sulbactam under continuous veno-venous hemodialysis (CVVHD) in intensive care patients with acute renal failure.
Drewelow, B; Ehmcke, H; Hickstein, H; Rohde, B; Werner, U, 1997
)
0.57
" The data on the PAE of Unasyn may be of clinical relevance in determining dosage regimens of the drug."( Postantibiotic effect of ampicillin/sulbactam against mycobacteria.
Harris, EB; Prabhakaran, K; Randhawa, B, 1999
)
0.58
" dosing schedule."( Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms.
Arenoso, HJ; Bantar, C; Blanco, M; Fernandez Canigia, L; Jasovich, A; Montoto, M; Nicola, F; Smayevsky, J; Soutric, J, 2001
)
0.53
" Ampicillin 2 g-sulbactam 1 g every 3 hours was administered based on history of therapeutic failure of traditional dosing in our thermal injury population."( Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis.
Ackerman, BH; Cawley, MJ; Lee, S; Suh, C, 2002
)
0.94
" The concentrations of cefoperazone and sulbactam in serum and, when possible, in urine and bile collected over one dosing interval were measured by high-pressure liquid chromatography."( Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients.
Agarwala, S; Gayowski, T; Mirani, A; Muder, RR; Venkataramanan, R, 2002
)
0.86
"The pharmacokinetics of a 2:1 ampicillin-sulbactam combination in six rabbits, after intravenous and intramuscular injection at a single dosage of 20 mg/kg bodyweight (13."( Pharmacokinetics of an ampicillin/sulbactam (2:1) combination in rabbits.
Cárceles, CM; Escudero, E; Serrano, JM; Vicente, MS, 2002
)
0.86
" Four different mathematical functions were tried to explore the dosimetric features of SS and a linear function of applied dose described best the dose-response data obtained for stable species, that is, radical B, in the dose range of 0-10 kGy."( ESR investigation of gamma irradiated sulbactam sodium.
Korkmaz, M; Ozbey, T; Yurus, S, 2004
)
0.59
" Dosage of Nitric oxide, count of eosinophil, lymphocytes, monocytes, and neutrophils in blood and peritoneal exsudte were done."( [Therapeutical and inflammatory response in rats with secondary peritonitis and topical use of ampicilin/sulbactam].
Aguiar, JL; Castro, CM; Kreimer, F; Lacerda, CM; Lisboa Júnior, F; Reis, T, 2005
)
0.54
" CI dosing has the additional advantage that less drug is necessary."( Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.
Glück, T; Herzig, H; Kees, F; Langgartner, J; Lehn, N, 2007
)
0.59
" As these concentrations were below concentrations reported after single dosing studies and below those considered to be minimally inhibitory, death was presumed to have been caused by hypersensitivity and not an overdose."( A fatal case of suspected anaphylaxis with cefoperazone and sulbactam: LC-MS analysis.
Inoue, H; Iwata, Y; Kanamori, T; Kishi, T; Kuwayama, K; Miyaguchi, H; Tsujikawa, K, 2008
)
0.59
" Dosage was adjusted according to creatinine clearance."( Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia.
Betrosian, AP; Douzinas, EE; Frantzeskaki, F; Xanthaki, A, 2008
)
0.61
" 67% and 50% of a 6- and 8-h dosing interval, respectively)."( Intravenous amoxicillin-sulbactam against Escherichia coli: optimizing the dose, component ratio and infusion time using a human pharmacodynamic model.
Arenoso, HJ; Bantar, C; Berger, MA; Fernandez Canigia, L; Soutric, JL, 2009
)
0.66
" Thus, we sought to search the optimal dosing strategy for this formulation through an ex vivo pharmacodynamic human model against Acinetobacter baumanniii."( Pharmacodynamic assessment of Amoxicillin-Sulbactam against Acinetobacter baumannii: searching the optimal dose and infusion time through a human ex-vivo model.
Arenoso, HJ; Bantar, C; Berger, MA; Canigia, LF; Soutric, JL, 2009
)
0.62
"019) than those with the genes chromosomally encoded, which is most likely due to increased gene dosage provided by the higher copy number of associated plasmids."( Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
Chang, FY; Chen, TL; Fung, CP; Hsueh, PR; Ko, WC; Kuo, SC; Lee, YT; Siu, LK, 2010
)
0.36
" Despite its frequent use in intensive care units, there are no available dosing recommendations for patients with AKI undergoing renal replacement therapy."( Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis.
Broll, M; Burhenne, H; Burkhardt, O; Clajus, C; Hafer, C; Kaever, V; Kielstein, JT; Knitsch, W; Lorenzen, JM, 2012
)
0.66
" There was no significant accumulation using a twice-daily dosage of 2 g/1 g ampicillin/sulbactam."( Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis.
Broll, M; Burhenne, H; Burkhardt, O; Clajus, C; Hafer, C; Kaever, V; Kielstein, JT; Knitsch, W; Lorenzen, JM, 2012
)
0.89
"3 m(2); blood and dialysate flow, 160 ml/min; treatment time, 480 minutes), a twice-daily dosing schedule of at least 2 g/1 g ampicillin/sulbactam, with one dose given after ED, should be used to avoid underdosing."( Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis.
Broll, M; Burhenne, H; Burkhardt, O; Clajus, C; Hafer, C; Kaever, V; Kielstein, JT; Knitsch, W; Lorenzen, JM, 2012
)
0.87
" This study aimed to use renal function to determine the most appropriate timing for intraoperative repeated dosing of ampicillin-sulbactam, a commonly used prophylactic antibiotic, to maintain adequate concentrations throughout the course of surgery."( Pharmacokinetics of ampicillin-sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery.
Iguro, Y; Ikawa, K; Imoto, Y; Ishida, S; Matsumoto, K; Morikawa, N; Okano, Y; Shimodozono, Y; Takeda, Y; Watanabe, E; Yamada, K; Yamamoto, H; Yokoyama, Y, 2012
)
0.87
" In our patient, intraperitoneal dosing of polymyxin B was determined based on limited published pharmacokinetic and pharmacodynamic data."( Successful treatment of extensively drug-resistant Acinetobacter baumannii peritoneal dialysis peritonitis with intraperitoneal polymyxin B and ampicillin-sulbactam.
Esterly, JS; Fitzpatrick, MA; Postelnick, MJ; Sutton, SH,
)
0.33
"The aim of this study was to reveal population pharmacokinetics and assess the efficacies of various dosage regimens of sulbactam in terms of the probability of target attainment with this agent over a range of MICs."( Pharmacodynamics modeling to optimize dosage regimens of sulbactam.
Aeinlang, N; Jaruratanasirikul, S; Jullangkoon, M; Wongpoowarak, W, 2013
)
0.84
" In elderly patients without renal impairment and/or in severe infection with less susceptible pathogens, more frequent dosing of ampicillin 2 g/sulbactam 1 g can be necessary to avoid the risk of underdosing in CAP."( Ampicillin/sulbactam in elderly patients with community-acquired pneumonia.
Drewelow, B; Frimmel, S; Klammt, S; Loebermann, M; Majcher-Peszynska, J; Mundkowski, RG; Reisinger, EC; Welte, T, 2014
)
0.99
" However, when the MPCs of dual-drug therapy were in conjunction with clinical pharmacokinetic profiles, combinations may not strictly curb the occurrence of resistance at current dosage regimen."( In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
Bai, N; Cai, X; Cai, Y; Cui, J; Liang, B; Ni, W; Wang, R, 2013
)
0.62
" The therapeutic challenges for ensuring achievement of optimal dosing of SAM result partly from bacterial susceptibility but also from the pharmacokinetic (PK) alterations common to β-lactam agents in critical illness."( Ampicillin/sulbactam: its potential use in treating infections in critically ill patients.
Adnan, S; Lipman, J; Paterson, DL; Roberts, JA, 2013
)
0.78
" Simulations were performed to investigate the effects of different dosing intervals on exposure and time above MIC in various degrees of renal impairment."( Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
Marshall, S; Muto, C; Shoji, S; Soto, E; Tomono, Y, 2014
)
0.66
" These findings provide useful information and augment evidence for the established dosage regimens in patients with various degrees of renal impairment."( Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
Marshall, S; Muto, C; Shoji, S; Soto, E; Tomono, Y, 2014
)
0.66
" The developed analytical methods did not show any interference of the excipients when applied to pharmaceutical dosage form."( Ultraviolet spectrophotometry (dual wavelength and chemometric) and high performance liquid chromatography for simultaneous estimation of meropenem and sulbactam sodium in pharmaceutical dosage form.
Borkhatariya, DV; Marwada, KR; Patel, AJ; Patel, BD; Patel, JB; Patel, NS, 2014
)
0.6
" This is necessary because optimisation of dosing regimens should be based on PK/PD analysis."( Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
Ikawa, K; Matsumoto, K; Morikawa, N; Nakamura, K; Shigemi, A; Takeda, Y; Ueno, K; Umezaki, Y; Watanabe, E; Yokoyama, Y, 2014
)
0.66
" This study aimed to determine the most appropriate timing for intraoperative repeated dosing of ampicillin-sulbactam, a commonly used antibiotic prophylaxis regimen, to maintain adequate concentrations throughout the course of cardiovascular surgery with cardiopulmonary bypass (CPB)."( Pharmacokinetics of Prophylactic Ampicillin-Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass.
Ikawa, K; Imoto, Y; Matsumoto, K; Morikawa, N; Takeda, Y; Watanabe, E; Yamamoto, H; Yokoyama, Y, 2015
)
0.89
" Efficacies of various FDC dosage regimens over a range of minimum inhibitory concentrations (MICs) were assessed by Monte Carlo simulations using population-PK parameters of infected/healthy subjects."( Population Pharmacokinetics of Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects.
Chaudhary, M; Sharma, VD; Singla, A; Taneja, M, 2016
)
0.67
"Cefoperazone/sulbactam (CFP/SUL) is a β-lactam/β-lactamase inhibitor combination with little data available for the development of effective dosing guidelines during continuous renal replacement therapy."( Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
An, R; Du, Z; Gao, C; Sun, Z; Tong, J; Yu, K, 2016
)
1.08
" For occasion 2, eight of nine patients achieved cefoperazone concentrations that were above the MIC for the entire dosing interval."( Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
An, R; Du, Z; Gao, C; Sun, Z; Tong, J; Yu, K, 2016
)
0.72
" Information regarding demographic, clinical and microbiological parameters, dosage and treatment duration, efficacy and adverse events (AEs) associated with the treatment were recorded."( Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study.
Ayub, SG; Chaudhary, M; Mir, MA,
)
0.38
" The significance of using drug combination is that it can reduce drug dosage requirements, reduce the toxic effects of agents and prevent or delay the emergence of drug resistance."( In vitro interactions of ambroxol hydrochloride or amlodipine in combination with antibacterial agents against carbapenem-resistant Acinetobacter baumannii.
Li, X; Lu, C; Sun, S; Wang, D; Wang, Y, 2020
)
0.56
" Hence, there is a strong rationale to individualize anti-infective dosing in these patients by using therapeutic drug monitoring (TDM)."( Determination of Total and Unbound Meropenem, Imipenem/Cilastatin, and Cefoperazone/Sulbactam in Human Plasma: Application for Therapeutic Drug Monitoring in Critically Ill Patients.
Dang, ZL; Li, B; Qin, HY; Rao, Z; Wei, YH; Wu, XA; Zhu, L, 2020
)
0.78
"This study sought to investigate whether dosing frequency (the number of doses per day) affects the antimicrobial efficacy and safety of ampicillin/sulbactam (ABPC/SBT) in Japanese elderly pneumonia patients treated with ABPC/SBT at 6 g/day."( Effects of dosing frequency on the clinical efficacy of ampicillin/sulbactam in Japanese elderly patients with pneumonia: A single-center retrospective observational study.
Nozawa, K; Sato, H; Sato, VH; Sugiyama, E; Suzuki, H; Suzuki, T; Tajima, M; Takahashi, K; Yoshii, M, 2021
)
1.06
" aeruginosa, 2 was shown to have dose-dependent efficacy at 50 and 100 mg/kg q6h dosing in a mouse thigh infection model."( A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
Bethel, CR; Bonomo, RA; Goldberg, JA; Hoyer, D; Hujer, AM; Hujer, KM; Jacobs, MR; Kreiswirth, BN; Kumar, V; Marshall, SH; Papp-Wallace, KM; Perez, F; Plummer, MS; Spencer, EJ; van den Akker, F; van Duin, D, 2021
)
0.62
" It is important to optimize the dose and dosing interval of ampicillin-sulbactam because in patients with decreased renal function and low skeletal muscle mass, such as the elderly, excess drug may burden renal function."( Dosing Optimization of Ampicillin-Sulbactam Based on Cystatin C in Elderly Patients with Pneumonia.
Enoki, Y; Ikawa, K; Matsubara, K; Matsumoto, K; Morikawa, N; Ohshige, T; Shigemi, A; Takeda, Y; Terazono, H; Watanabe, E; Yokoyama, Y, 2021
)
1.13
"We aimed to develop population pharmacokinetic (PK) models of ampicillin and sulbactam using pooled data analysis and to optimize dosing regimens of ampicillin-sulbactam (combination ratio of 2:1) in pediatric patients."( Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data.
Ikawa, K; Ishihara, N; Morikawa, N; Naora, K; Onita, T; Tamaki, H; Yano, T, 2022
)
1.22
" (Food and Drug Administration-approved maximum dosage in United States) might be better than 45 mg/kg 3 times daily (within approved dosage in Japan) to cover many pathogens."( Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data.
Ikawa, K; Ishihara, N; Morikawa, N; Naora, K; Onita, T; Tamaki, H; Yano, T, 2022
)
0.99
" Target pharmacodynamic indices were used to evaluate whether pediatric and adult dosing regimens provided sufficient coverage."( Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Lv, Z; Oo, C; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S, 2022
)
0.96
" In a virtual pediatric population aged from 2 to < 18 years, the interpretive breakpoints were achieved in 85-90% of subjects for their targeted pharmacodynamic indices after administration of pediatric dosing regimens consisting of 30 mg/kg of meropenem, and 40 mg/kg of sulbactam three times daily as a 3-h or continuous infusion and 5 mg/kg/day of colistin base activity."( Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling.
Lv, Z; Oo, C; Sy, SKB; Yu, M; Zhang, J; Zhu, P; Zhu, S, 2022
)
1.14
"This study investigated the population pharmacokinetics of ampicillin and sulbactam in patients with a wide range of renal functions and sought to define dosing approaches that have a high likelihood for optimising drug exposure."( Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients.
Abdul-Aziz, MH; Cotta, MO; Lukas, DL; Parker, S; Roberts, JA; Setiawan, E; Sosilya, H; Wallis, SC; Widjanarko, D, 2023
)
1.38
" Approved dosing regimens of ampicillin-sulbactam were sufficient against MICs ≤ 8 and ≤ 4 mg/L, respectively."( Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients.
Abdul-Aziz, MH; Cotta, MO; Lukas, DL; Parker, S; Roberts, JA; Setiawan, E; Sosilya, H; Wallis, SC; Widjanarko, D, 2023
)
1.41
"The described dosing regimen for ampicillin/sulbactam is safe with respect to the defined MIC breakpoints for ampicillin, and continuous subtherapeutic concentration is unlikely."( Evaluation of continuous ampicillin/sulbactam infusion in critically ill patients.
Baehner, T; Passon, SG; Schmidt, AR; Velten, M; Wittmann, M, 2023
)
1.45
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
penicillanic acids
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (46)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency100.00000.631035.7641100.0000AID504339
AR proteinHomo sapiens (human)Potency17.65880.000221.22318,912.5098AID743035; AID743063
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.88320.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency13.33320.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.91920.000214.376460.0339AID720691; AID720692; AID720719
retinoid X nuclear receptor alphaHomo sapiens (human)Potency2.21640.000817.505159.3239AID1159527; AID1159531
farnesoid X nuclear receptorHomo sapiens (human)Potency3.34890.375827.485161.6524AID743217
estrogen nuclear receptor alphaHomo sapiens (human)Potency9.58370.000229.305416,493.5996AID743069; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency5.95530.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency3.79020.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency18.99590.023723.228263.5986AID743223
activating transcription factor 6Homo sapiens (human)Potency0.01200.143427.612159.8106AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.68460.057821.109761.2679AID1159526; AID1159528
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.27660.000627.21521,122.0200AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency0.06680.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase Escherichia coliIC50 (µMol)6.20000.01002.09336.2000AID326273
Beta-lactamase Escherichia coliIC50 (µMol)250.00000.02600.02900.0320AID394491
Beta-lactamase Shouchella clausiiIC50 (µMol)0.07500.00400.05470.0850AID373218
Beta-lactamase Pseudomonas aeruginosaIC50 (µMol)0.37000.06000.17000.3700AID511293
Beta-lactamase Pseudomonas aeruginosaIC50 (µMol)3.00000.10001.70003.0000AID495659
Beta-lactamase Aeromonas allosaccharophilaIC50 (µMol)4.00004.00004.00004.0000AID584845
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Beta-lactamaseStaphylococcus aureusIC50 (µMol)6.50000.08001.95096.5000AID43913
Beta-lactamaseEscherichia coli K-12IC50 (µMol)65.93330.01502.46578.0000AID38400; AID44068; AID44069
Beta-lactamaseEnterobacter cloacaeIC50 (µMol)29.50000.10001.87457.7000AID44079; AID44080; AID584977
Beta-lactamase SHV-1Klebsiella pneumoniaeKi1.50000.22001.24002.0000AID1801066
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)50.00000.00022.45859.9600AID1910632
Beta-lactamase OXA-1Escherichia coliIC50 (µMol)22.00003.20004.00004.8000AID43565
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)65.90000.00031.38338.4000AID44068
Beta-lactamasePseudomonas aeruginosa PAO1IC50 (µMol)27.00000.12801.69164.6000AID584978
Angiotensin-converting enzymeRattus norvegicus (Norway rat)IC50 (µMol)66.00000.00090.33223.0300AID38400
Beta-lactamase TEMEscherichia coliIC50 (µMol)56.91670.00191.761810.0000AID209020; AID326275; AID43090; AID43566; AID44070; AID44071
Beta-lactamase TEMEscherichia coliKi0.80000.02701.82347.3000AID43582
Beta-lactamase Acinetobacter pittiiIC50 (µMol)1.12001.12001.12001.1200AID555229
Beta-lactamase Acinetobacter pittiiIC50 (µMol)7.75807.75807.75807.7580AID555230
Beta-lactamase Pseudomonas aeruginosaIC50 (µMol)3.00000.10001.70003.0000AID495660
Class D beta-lactamaseBrachyspira pilosicoliIC50 (µMol)12.00000.16001.08002.0000AID519637
Beta-lactamase Serratia fonticolaIC50 (µMol)22.70006.90006.90006.9000AID374027
Beta-lactamase Escherichia coliIC50 (µMol)2.40002.40002.40002.4000AID531609
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-lactamase class B VIM-2 Pseudomonas aeruginosaKm320.00002.00006.65009.4000AID531315
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (166)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (69)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (38)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (238)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID516154Antibacterial activity against Pulsotype B Acinetobacter genomosp. 3 isolate 8 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID584974Inhibition of beta-lactamase KPC-2 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID727643Binding affinity to wild type Beta-lactamase SHV-1 in Escherichia coli DH10B assessed as melting temperature at 50 uM by circular dichroism analysis (Rvb = 54.2 degC)2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID518819Antibacterial activity against Acinetobacter genomosp. 3 isolates assessed as percent of resistance isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID585188Inhibition of Beta-lactamase GES-7 K104, G170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID44080In vitro inhibitory activity against Beta-lactamase TEM-1 of class A enzyme2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone.
AID555231Inhibition of Acinetobacter genomosp. 3 isolate 195 ADC-182009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID516155Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 10 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID584977Inhibition of Enterobacter cloacae beta-lactamase P99 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID510985Antimicrobial activity against Acinetobacter baumannii 1327 after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID44220Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 100.0 umol/L2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
AID511011AUC in C57BL/6 mouse pneumonia model at 60 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID43090Inhibitory activity against Beta-lactamase from Bacillus sp. using penicillin G as substrate1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID64067Minimum inhibitory activity against Escherichia coli A96751981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1782800Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-345 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID510984Antimicrobial activity against Acinetobacter baumannii 1417 after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID278065Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from deployed military patient2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID44068Inhibitory activity against AmpC (class C) beta-lactamase1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C beta-lactamases I.
AID531316Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID524593Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolate Kpn-DK2 by broth microdilution method2010Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
AID584973Inhibition of beta-lactamase SHV-4 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID510980Antimicrobial activity against Acinetobacter baumannii 14172010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID511102Cmax in New Zealand rabbit meningitis model at 30 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID44070Inhibitory activity against TEM-1 (class A) beta-lactamase1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
6-(1-Hydroxyalkyl)penam sulfone derivatives as inhibitors of class A and class C beta-lactamases I.
AID727648Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234R mutant by CLSI agar dilution method in presence of ampicillin2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID422953Antibacterial activity against heteroresistant Acinetobacter baumannii-calcoaceticus complex isolated from total cumulative patients preexposed to 325 to 900 mg of drug after 20 to 24 hrs by broth microdilution method2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Colistin heteroresistance in acinetobacter and its association with previous colistin therapy.
AID1895188Binding affinity to sulfatase in human T98G cells assessed as reduction in fluorescence intensity at 125 uM in presence of 2-(2-Morpholinoethyl)-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1H-benzo[de]-isoquinoline2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme.
AID516152Antibacterial activity against Pulsotype K Acinetobacter genomosp. 3 isolate 6 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID394491Inhibition of Escherichia coli beta-lactamase ACC42007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
AID44069Inhibitory activity against AmpC (class C) beta-lactamase1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
6-(1-Hydroxyalkyl))penam sulfone derivatives as inhibitors of class A and class C beta-lactamases II.
AID727647Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234A mutant by CLSI agar dilution method in presence of ampicillin2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID44218Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 1.0 umol/L2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
AID727652Inhibition of wild type Beta-lactamase SHV-1 in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID531313Activity of Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID43582Inhibition constant (Ki) for TEM-1 beta-lactamase1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
N-aryl 3-halogenated azetidin-2-ones and benzocarbacephems, inhibitors of beta-lactamases.
AID727640Binding affinity to Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B assessed as change in secondary structure at 50 uM by circular dichroism analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID326273Inhibition of Escherichia coli beta-lactamase SCO12007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID64066Minimum inhibitory activity against Escherichia coli A212231981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID511003Ratio of Cmax to MIC for Acinetobacter baumannii 1327 in pharmacokinetic-pharmacodynamic C57BL/6 mouse pneumonia model at 60 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID1782796Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-325 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID1782805Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-399 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID510981Antimicrobial activity against Acinetobacter baumannii 13272010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID510973Antimicrobial activity against Acinetobacter baumannii infected in C57BL/6 mouse model assessed as reduction in bacterial count per gram of lung at total dose of 240 mg/kg/day, im administered as four divided doses after 72 hrs (RVb = 10.6+/-0.27 No_unit)2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID727651Inhibition of Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B by Henri-Michaelis-Menten steady state equation analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID117521Beta-lactamase inhibitory activity against Staphylococcus aureus A15091 using oral mouse protection test in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID1782808Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-459 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID374027Inhibition of Serratia fonticola UTAD54 SFC1 beta lactamase expressed in Escherichia coli BL21(DE3) by SDS-PAGE2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Biochemical Characterization of SFC-1, a class A carbapenem-hydrolyzing beta-lactamase.
AID1578805Inhibition of beta-lactamase in Staphylococcus epidermidis 01B116 assessed as potentiation of benzylpenicillin-induced antibacterial activity by measuring benzylpenicillin MIC at 3.12 ug/ml (Rvb >25 ug/ml)2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID727645Ratio of Kcat to Kinact for wild type Beta-lactamase SHV-1 in Escherichia coli DH10B2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID531314Ratio of Kcat to Km for Pseudomonas aeruginosa beta-lactamase VIM-7 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1782814Antibacterial activity against carbapenem susceptible Acinetobacter baumannii isolate PR-434 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID555230Inhibition of Acinetobacter genomosp. 3 isolate 103 ADC-162009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID52214Inhibitory activity against cephalosporinase from Proteus morganii TH-64 using cephalothin (40 uM) as a substrate1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID510983Antimicrobial activity against Acinetobacter baumannii 5062010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID518818Antibacterial activity against Acinetobacter genomosp. 3 isolates by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID1578806Inhibition of beta-lactamase in Haemophilus influenzae 54A042 assessed as potentiation of benzylpenicillin-induced antibacterial activity by measuring benzylpenicillin MIC at 1.56 ug/ml (Rvb = 200 ug/ml)2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID43739Beta-lactamase inhibitory activity from Klebsiella pneumoniae A20634(TEM) and minimum protective concentration was reported1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID584978Inhibition of Pseudomonas aeruginosa beta-lactamase AmpC assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID531609Inhibition of Escherichia coli JM109 beta-lactamase SHV-112008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID531315Activity of Pseudomonas aeruginosa beta-lactamase VIM-2 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID44219Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 10.0 umol/L2002Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6
Design, synthesis and bioactivity evaluation of tribactam beta lactamase inhibitors.
AID117522Beta-lactamase inhibitory activity against Staphylococcus aureus A20379 using oral mouse protection test in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID560135Inhibition of recombinant beta-lactamase RTG4 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID584975Inhibition of beta-lactamase CTX-M-15 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID516151Antibacterial activity against Pulsotype M Acinetobacter genomosp. 3 isolate 5 containing IMP-1, OXA-58, ADC-43, ISAba2, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID326275Inhibition of Escherichia coli K12 TEM12007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID510994Ratio of AUC to MIC for Acinetobacter baumannii 1327 in pharmacokinetic-pharmacodynamic C57BL/6 mouse pneumonia model at 60 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID531608Inhibition of Escherichia coli Inhibitor-resistant beta-lactamase SHV-562008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Molecular and biochemical characterization of SHV-56, a novel inhibitor-resistant beta-lactamase from Klebsiella pneumoniae.
AID1578807Inhibition of beta-lactamase in Bacteroides fragilis 78C004 assessed as potentiation of benzylpenicillin-induced antibacterial activity by measuring benzylpenicillin MIC at 3.12 ug/ml (Rvb = 200 ug/ml)2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID511014Half life in New Zealand rabbit meningitis model at 30 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID572899Inhibition of Beta-lactamase TEM-12009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID727641Binding affinity to wild type Beta-lactamase SHV-1 in Escherichia coli DH10B assessed as change in secondary structure at 50 uM by circular dichroism analysis2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID560136Inhibition of recombinant beta-lactamase RTG3 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay2009Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7
Genetic and biochemical characterization of the first extended-spectrum CARB-type beta-lactamase, RTG-4, from Acinetobacter baumannii.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID340736Activity of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID531317Activity of Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID516157Antibacterial activity against Pulsotype J Acinetobacter genomosp. 3 isolate 15 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID510999Ratio of Cmax to MIC for Acinetobacter baumannii 1327 in pharmacokinetic-pharmacodynamic New Zealand rabbit meningitis model at 30 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID1782815Antibacterial activity against carbapenem susceptible Acinetobacter baumannii isolate PR-452 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID510990Ratio of AUC to MIC for Acinetobacter baumannii 1327 in pharmacokinetic-pharmacodynamic New Zealand rabbit meningitis model at 30 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID548266Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 by competitive assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID534361Antibacterial activity against Acinetobacter baumannii GIL1 isolate harboring intrinsic blaOXA-51/69-like gene by Etest method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
Carbapenem-resistant Acinetobacter baumannii isolates expressing the blaOXA-23 gene associated with ISAba4 in Belgium.
AID117524Beta-lactamase inhibitory activity against Staphylococcus aureus A9606 using oral mouse protection test in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID422882Antimicrobial activity against Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis by broth microdilution assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID516153Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 7 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID117520Beta-lactamase inhibitory activity against Escherichia coli A21223 using oral mouse protection test in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID38400In vitro inhibitory concentration against AmpC enzyme2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID510969Antimicrobial activity against Acinetobacter baumannii infected in C57BL/6 mouse model assessed as reduction in bacterial count in blood at total dose of 240 mg/kg/day, im administered as four divided doses after 72 hrs2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID584845Inhibition of Aeromonas allosaccharophila AL-1 beta-lactamase PER62010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
PER-6, an extended-spectrum beta-lactamase from Aeromonas allosaccharophila.
AID585192Inhibition of Beta-lactamase GES-13 K104, N170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID278066Antimicrobial activity against Acinetobacter baumannii-calcoaceticus complex isolated from nondeployed military patient2007Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1
Susceptibility of acinetobacter strains isolated from deployed U.S. military personnel.
AID1782813Antibacterial activity against carbapenem susceptible Acinetobacter nosocomialis isolate PR-491 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID511106Cmax in C57BL/6 mouse pneumonia model at 60 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID44079In vitro inhibitory activity against Beta-lactamase AmpC of class C enzyme2003Journal of medicinal chemistry, Jun-19, Volume: 46, Issue:13
Spirocyclopropyl beta-lactams as mechanism-based inhibitors of serine beta-lactamases. Synthesis by rhodium-catalyzed cyclopropanation of 6-diazopenicillanate sulfone.
AID1782804Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-387 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID585190Inhibition of Beta-lactamase GES-5 E104, S170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID548267Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant by competitive assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID340738Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis relative to control2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID510987Antimicrobial activity against Acinetobacter baumannii 506 after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID510982Antimicrobial activity against Acinetobacter baumannii 9402010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID510986Antimicrobial activity against Acinetobacter baumannii 940 after 24 hrs by time-kill assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID43098Beta-lactamase inhibitory activity from Bacillus fragilis A-22,695 and minimum protective concentration was reported1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID548270Ratio of Ki for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant to Ki for Klebsiella pneumoniae beta-lactamase KPC-2 T237S mutant by competitive assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID549688Inhibition of beta-lactamase TEM-12011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Modifications of the C6-substituent of penicillin sulfones with the goal of improving inhibitor recognition and efficacy.
AID516156Antibacterial activity against Pulsotype I Acinetobacter genomosp. 3 isolate 11 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID516148Antibacterial activity against Pulsotype C Acinetobacter genomosp. 3 isolate 1 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID1895185Inhibition of lysosome sulfatase (unknown origin) assessed as reduction in fluorescence intensity using 2-(2-Morpholinoethyl)-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1H-benzo[de]-isoquinoline-1,3(2H)-dione as s2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme.
AID13879Maximum Concentration of the compound.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Orally effective acid prodrugs of the beta-lactamase inhibitor sulbactam.
AID1782795Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-319 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID555229Inhibition of Acinetobacter genomosp. 3 isolate 65 ADC-142009Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3
Genetic variability among ampC genes from acinetobacter genomic species 3.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1782809Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-482 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID44046Beta-lactamase inhibitory activity from Staphylococcus aureus A9606 and minimum protective concentration was reported1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID516158Antibacterial activity against Pulsotype D Acinetobacter genomosp. 3 isolate 18 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, repAcil, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID1895191Cytotoxicity against human T98G cells assessed as reduction in cell viability at 3.5 to 350 uM incubated for 48 hrs by MTT assay relative to control2021Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12
New Protocol-Guided Exploitation of a Lysosomal Sulfatase Inhibitor to Suppress Cell Growth in Glioblastoma Multiforme.
AID373218Inhibition of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3)2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Molecular and biochemical characterization of the chromosome-encoded class A beta-lactamase BCL-1 from Bacillus clausii.
AID209020In vitro inhibitory concentration against TEM-1 enzyme2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
AID422883Antimicrobial activity against 8 ug/ml colistin-subcultured Acinetobacter baumannii-Acinetobacter calcoaceticus complex isolated from diabetic patient with calcaneal osteomyelitis and bacteremia by broth microdilution assay2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Development of colistin-dependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex.
AID1782806Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-401 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID511293Inhibition of Pseudomonas aeruginosa GES-13 beta lactamase2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
AID232106Ratio is calculated as AUC to AUC of Sulbactam derivative (control)1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Orally effective acid prodrugs of the beta-lactamase inhibitor sulbactam.
AID727650Antimicrobial activity against Escherichia coli DH10B by CLSI agar dilution method in presence of ampicillin2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID511119T>MIC in Acinetobacter baumannii infected New Zealand rabbit meningitis model at 30 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID117523Beta-lactamase inhibitory activity against Staphylococcus aureus A20649 using oral mouse protection test in mice1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID1782797Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-326 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID511005AUC in New Zealand rabbit meningitis model at 30 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID496600Inhibition of Escherichia coli DH10B beta-lactamase KPC-2 assessed as residual activity at 25 to 200 uM after 15 mins by diode array spectrophotometry2010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID1782810Antibacterial activity against carbapenem susceptible Acinetobacter nosocomialis isolate PR-362 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID52216Inhibitory activity against cephalosporinase from Proteus vulgaris TH-147 using cephalexin (40 uM) as a substrate1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID422500Inhibition of Carnobacterium divergens BM4489 penicillinase Cad-12008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Genetic and biochemical characterization of CAD-1, a chromosomally encoded new class A penicillinase from Carnobacterium divergens.
AID516149Antibacterial activity against Pulsotype L Acinetobacter genomosp. 3 isolate 2 containing IMP-8, OXA-58, ADC-43, ISAba1, ISAba3, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID519637Inhibition of Brachyspira pilosicoli beta-lactamase OXA-63 expressed in Escherichia coli BL21 (DE3) assessed as reduction in nitrocefin hydrolysis by spectrophotometry relative to oxacillin2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
Genetic and biochemical characterization of OXA-63, a new class D beta-lactamase from Brachyspira pilosicoli BM4442.
AID1808873Inhibition beta lactamase PDC-1 in Pseudomonas aeruginosa PAO1 using nitrocefin as substrate measured by 96 well microtitre plate
AID43740Minimum protective concentration of compound required against Klebsiella pneumoniae A20634 beta-lactamase catalyzed hydrolysis1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID727644Ratio of Kcat to Kinact for Beta-lactamase SHV-1 K234R protein mutant in Escherichia coli DH10B2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID1578804Inhibition of penicillinase in Staphylococcus aureus 01A400 assessed as potentiation of benzylpenicillin-induced antibacterial activity by measuring benzylpenicillin MIC at 3.12 ug/ml (Rvb = 200 ug/ml)2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID43913Inhibitory activity against Penicillinase from Staphylococcus aureus TH-14 using piperacillin (40 uM) as a substrate1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID1782794Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-314 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID200258Minimum inhibitory activity against Staphylococcus aureus A150911981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID584976Inhibition of beta-lactamase TEM- 1 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor.
AID43116Minimum protective concentration of compound required against Bacteroides fragilis A-22,695 beta-lactamase catalyzed hydrolysis1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID511115T>MIC in Acinetobacter baumannii infected C57BL/6 mouse pneumonia model at 60 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID586057Antimicrobial activity against Acinetobacter baumannii clinical isolate harboring plasmid encoded ISAba1-blaOXA-51-like gene with nuc upstream sequence by agar dilution method2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Emergence and Distribution of Plasmids Bearing the blaOXA-51-like gene with an upstream ISAba1 in carbapenem-resistant Acinetobacter baumannii isolates in Taiwan.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1782798Antibacterial activity against carbapenem susceptible Acinetobacter baumannii isolate PR-340 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID727649Antimicrobial activity against Escherichia coli DH10B expressing wild type Beta-lactamase SHV1 gene by CLSI agar dilution method in presence of ampicillin2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1782816Antibacterial activity against carbapenem susceptible Acinetobacter baumannii isolate PR-464 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID496596Ratio of Kcat to Kinact for Escherichia coli DH10B beta-lactamase KPC-22010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID548268Inhibition of Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237A mutant by competitive assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID1782812Antibacterial activity against carbapenem susceptible Acinetobacter nosocomialis isolate PR-412 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID531318Ratio of Kcat to Km for Escherichia coli beta-lactamase VIM-1 by spectrophotometry2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
AID1782811Antibacterial activity against carbapenem susceptible Acinetobacter nosocomialis isolate PR-365 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID549689Inhibition of beta-lactamase PDC-32011Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1
Modifications of the C6-substituent of penicillin sulfones with the goal of improving inhibitor recognition and efficacy.
AID495660Inhibition of Pseudomonas aeruginosa 51170 beta-lactamase BEL-12010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID44048Minimum protective concentration of compound required against Staphylococcus aureus A9606 beta-lactamase catalyzed hydrolysis1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(acyloxy)methyl]-2-methylpenam-3 alpha-carboxylic acid 1,1-dioxides.
AID1910632Inhibition of recombinant SARS-CoV-2 Main protease using ALNDFSNSGSDVLYQPPQTSITSAVLQ/SGFRKMAFPS-NH2 as substrate preincubated for 45 to 75 mins followed by substrate addition measured after 6 mins by SPE-MS inhibition assay2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.
AID496597Ratio of Kinact to Km for Escherichia coli DH10B beta-lactamase KPC-22010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID572898Inhibition of Enterobacter cloacae Beta-lactamase AmpC2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID200259Minimum inhibitory activity against Staphylococcus aureus A203091981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID727646Antimicrobial activity against Escherichia coli DH10B expressing Beta-lactamase SHV K234X mutant by CLSI agar dilution method in presence of ampicillin2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase.
AID1782803Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-384 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID51552In vitro inhibitory concentration against CCRA enzyme2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Allyl and propargyl substituted penam sulfones as versatile intermediates toward the syntheses of new beta-lactamase inhibitors.
AID340737Ratio of Kcat to Km of Chryseobacterium indologenes metallo-beta-lactamase IND-5 expressed in Escherichia coli BL21(DE3) assessed as substrate hydrolysis2007Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8
Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes.
AID26667Half-life period for disappearance of Sulbactam from rat.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Orally effective acid prodrugs of the beta-lactamase inhibitor sulbactam.
AID1782799Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-342 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID1782801Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-351 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID1782802Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-380 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID13532Area under curve (AUC) was determined1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Orally effective acid prodrugs of the beta-lactamase inhibitor sulbactam.
AID43566Inhibitory activity against Beta-lactamase type TEM2 (penicillinase) from Escherichia coli TEM2 using penicillin G (40 uM) as a substrate1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID43565Inhibitory activity against Beta-lactamase type OXA1 (penicillinase) from Escherichia coli OXA1 using ampicillin (40 uM) as a substrate1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and beta-lactamase inhibitory properties of 2 beta-[(1,2,3-triazol-1-yl)methyl]-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide and related triazolyl derivatives.
AID585189Inhibition of Beta-lactamase GES-2 E104, N170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID511017Half life in C57BL/6 mouse pneumonia model at 60 mg/kg, im2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID585187Inhibition of Beta-lactamase GES-1 E104, G170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID44071Inhibitory activity against TEM-1 (class A) beta-lactamase1999Bioorganic & medicinal chemistry letters, Apr-05, Volume: 9, Issue:7
6-(1-Hydroxyalkyl))penam sulfone derivatives as inhibitors of class A and class C beta-lactamases II.
AID326274Inhibition of Escherichia coli K12 CARB12007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.
AID516150Antibacterial activity against Pulsotype F Acinetobacter genomosp. 3 isolate 4 containing IMP-1, OXA-58, ADC-18, ISAba1, ISAba3, IS18, IS1008, intI1 genetic elements by agar dilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Molecular characterization of beta-lactamase genes and their genetic structures in Acinetobacter genospecies 3 isolates in Taiwan.
AID585191Inhibition of Beta-lactamase GES-6 K104, S170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry2010Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11
Comparative biochemical and computational study of the role of naturally occurring mutations at Ambler positions 104 and 170 in GES β-lactamases.
AID495659Inhibition of Pseudomonas aeruginosa 531 beta-lactamase BEL-22010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
AID200260Minimum inhibitory activity against Staphylococcus aureus A96061981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Synthesis and beta-lactamase inhibitory properties of 2 beta-(chloromethyl)-2 alpha-methylpenam-3 alpha-carboxylic acid 1,1-dioxide.
AID496594Ratio of Kcat to Km for Escherichia coli DH10B beta-lactamase KPC-22010Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
AID548269Ratio of Ki for Klebsiella pneumoniae 1534 beta-lactamase KPC-2 T237S mutant to Ki for Klebsiella pneumoniae wild type beta-lactamase KPC-2 by competitive assay2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1782807Antibacterial activity against carbapenem resistant Acinetobacter baumannii isolate PR-423 assessed as bacterial growth inhibition by microdilution method2021European journal of medicinal chemistry, Aug-05, Volume: 220A γ-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.
AID510977Antibacterial activity against Acinetobacter baumannii infected in C57BL/6 mouse model assessed as survival rate at total dose of 240 mg/kg/day, im administered as four divided doses measured after 72 hrs post last dose relative to control2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii.
AID572897Inhibition of Klebsiella pneumoniae Beta-lactamase SHV-12009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum {beta}-lactamase inhibitor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1801066Steady-State Kinetics Assay from Article 10.1021/bi501197t: \\Detecting a quasi-stable imine species on the reaction pathway of SHV-1 u00DF-lactamase and 6u00DF-(hydroxymethyl)penicillanic acid sulfone.\\2015Biochemistry, Jan-27, Volume: 54, Issue:3
Detecting a quasi-stable imine species on the reaction pathway of SHV-1 β-lactamase and 6β-(hydroxymethyl)penicillanic acid sulfone.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,663)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990336 (20.20)18.7374
1990's471 (28.32)18.2507
2000's326 (19.60)29.6817
2010's363 (21.83)24.3611
2020's167 (10.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 94.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index94.94 (24.57)
Research Supply Index7.67 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index174.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (94.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials297 (16.11%)5.53%
Reviews115 (6.24%)6.00%
Case Studies280 (15.18%)4.05%
Observational12 (0.65%)0.25%
Other1,140 (61.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (35)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections [NCT00368537]Phase 4550 participants (Actual)Interventional2006-09-30Completed
Antibiotic Prophylaxis for Early Ventilator-associated Pneumonia in Neurological Patients: A Randomized Trial [NCT01118403]Phase 40 participants (Actual)Interventional2011-03-31Withdrawn(stopped due to He could not be started due to lack of funds)
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Cefoperazone Sodium and Sulbactam Sodium Combination (1/1 g/Vial) After Intravenous Infusion of 1 g Cefoperazone Sodium and 1 g Sulbactam Sodium in Health [NCT05654090]Phase 414 participants (Anticipated)Interventional2022-08-25Active, not recruiting
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
A Randomized Controlled Trial Assessing Noninferiority of Three Antimicrobial Regimens for the Treatment of Grade III Open Fractures [NCT03560232]Phase 417 participants (Actual)Interventional2018-07-09Terminated(stopped due to Unable to recruit patients in a timely fashion and unable to recruit sufficient patients)
Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria [NCT03477422]Phase 3230 participants (Actual)Interventional2014-01-11Completed
Ampicillin / Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section: a Randomized Study [NCT01138852]Phase 4176 participants (Actual)Interventional2004-07-31Completed
A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex [NCT03894046]Phase 3207 participants (Actual)Interventional2019-09-05Completed
Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants [NCT01349738]200 participants (Anticipated)Observational2011-05-31Enrolling by invitation
Efficacy and Safety of CRO-SBT Performed in Children With Acute Bacterial Infection [NCT04066621]Phase 430 participants (Actual)Interventional2015-04-28Completed
Is an Antibiotic Prescription Required After Laparoscopic Cholecystectomy for Acute Calculous Cholecystitis? [NCT04290104]Phase 42 participants (Anticipated)Interventional2020-10-15Not yet recruiting
Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial [NCT05977868]Phase 4135 participants (Anticipated)Interventional2023-08-04Enrolling by invitation
The Effect of Nebulization of Alkaline Solution on Treating Extensively Drug Resistant A. Baumannii Pneumonia With Cefoperazone and Sulbactam Plus Minocycline: A Multi-center Randomized Study [NCT02060149]Phase 1/Phase 290 participants (Anticipated)Interventional2014-03-31Not yet recruiting
Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE) [NCT05922124]Phase 4734 participants (Anticipated)Interventional2024-01-31Not yet recruiting
Epidemiological Study on Drug-induced Coagulation Disorder Caused by Cefoperazone Sulbactam Sodium and Construction of Prediction Model [NCT05535309]8,000 participants (Anticipated)Observational2021-11-02Active, not recruiting
A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections [NCT00952796]Phase 4100 participants (Anticipated)Interventional2009-01-31Completed
A Prospective, Double-blind, Multi Center, Randomized Clinical Study to Compare the Efficacy and Safety of Ertapenem 3 Days Versus Ampicillin-Sulbactam 3 Days in the Treatment of Localized Community Acquired Intra-abdominal Infection (IAI). (T.E.A. Study [NCT00630513]Phase 4142 participants (Actual)Interventional2008-01-31Completed
A Study Evaluating Efficacy and Safety of Ceftriaxone Sodium and Sulbactam Sodium for Injection in the Treatment of Uncomplicated Urogenital Gonorrhea [NCT04202068]Phase 4113 participants (Actual)Interventional2015-07-03Completed
A Multicenter, Unblinded, Non-Comparative Study Of Unasyn-S 12 G/Day Evaluating The Safety And Efficacy In Japanese Adult Subjects With Community Acquired Pneumonia [NCT01189487]Phase 347 participants (Actual)Interventional2010-10-31Completed
Ciprofloxacin, Ampicillin-sulbactam and Placebo Prophylaxis in Laparoscopic Cholecystectomy. A Randomized Controlled Study [NCT01888822]Phase 4138 participants (Actual)Interventional2013-06-30Terminated
Multiple-dose Pharmacokinetics of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid During Haemodialysis in Longterm Haemodialysis Patients [NCT02007603]Phase 316 participants (Actual)Interventional2013-08-31Completed
Prospective, Multi-center, Randomized, Non-blind Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Sulbactam/Ampicillin in the Treatment of Pulmonary Abscess and Aspiration Pneumonia [NCT01045902]Phase 3139 participants (Actual)Interventional2001-02-28Completed
Phase IV Study of Determining the Efficacy of Ampicillin/Sulbactam Combination as Antibiotic Prophylaxis During Breast Cancer Surgery in Patients With a Body Mass Index (BMI) Over 25. [NCT00356148]Phase 4372 participants (Actual)Interventional2003-10-31Completed
The Impact of Cefepime and Unictam on Preventing Post-Cesarean Surgical Site Infections [NCT06048692]Phase 3213 participants (Actual)Interventional2023-01-01Active, not recruiting
Phase Ⅱ Study on Ceftazidime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection [NCT01601093]Phase 2288 participants (Anticipated)Interventional2011-11-30Suspended(stopped due to other project got priority)
Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections [NCT02688322]Phase 418 participants (Actual)Interventional2014-09-30Completed
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study. [NCT00463762]0 participants (Actual)Observational2007-05-31Withdrawn
A Multicenter, Open Label Trial Evaluating Intravenous Azithromycin Plus Intravenous Ampicillin/Sulbactam Followed by Oral Azithromycin Plus Intravenous Ampicillin/Sulbactam for the Treatment of Hospitalized Subjects With Community-Acquired Pneumonia (CAP [NCT00137007]Phase 4151 participants (Actual)Interventional2003-11-30Completed
Phase IV Study on Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection [NCT01760109]Phase 42,000 participants (Actual)Interventional2011-07-31Completed
A Phase I, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects [NCT02971423]Phase 1124 participants (Actual)Interventional2016-10-31Completed
A Phase I Study to Determine and Compare Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous ETX2514 and Sulbactam Administered to Healthy Adult Subjects [NCT03303924]Phase 130 participants (Actual)Interventional2017-08-21Completed
A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections [NCT00360607]Phase 4307 participants (Actual)Interventional2004-07-31Completed
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis [NCT03445195]Phase 280 participants (Actual)Interventional2018-01-17Completed
Efficacy of Preoperative Prophylactic Antibiotics in Preventing Complications in the Primary Repair of Cleft Palates [NCT00760006]Phase 2224 participants (Actual)Interventional2008-05-31Completed
Special Use-result Surveillance Of Unasyn-s (Kit) For Intravenous Use - A Surveillance On High-dose (>6 G Daily) Administration For Pneumonia, Lung Abscess And Peritonitis - [NCT01793688]982 participants (Actual)Observational2013-03-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00356148 (2) [back to overview]Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and no Prophylaxis (No Prophylaxis Group).
NCT00356148 (2) [back to overview]Overall SSI-related Prophylaxis and Treatment Cost in Patients With BMI Over 25 Who Received Prophylaxis (Prophylaxis Group) and Not (No Prophylaxis Group).
NCT00368537 (5) [back to overview]Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit
NCT00368537 (5) [back to overview]Number of Microbiologically Evaluable Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit
NCT00368537 (5) [back to overview]Inpatient Healthcare Resource Utilization on or Before Test-of-Cure - Number of Patients
NCT00368537 (5) [back to overview]Minimum Inhibitory Concentration (MIC) 50 and 90 by Baseline Isolate
NCT00368537 (5) [back to overview]Number of Microbiologically Evaluable Patients by Microbiologic Response at Test-of-Cure (TOC) Visit
NCT00760006 (1) [back to overview]Number of Participants With Fistula or Delayed Wound Healing Following Palatoplasty
NCT01189487 (5) [back to overview]The Tendency Toward Clinical Improvement (Investigator Assessment)
NCT01189487 (5) [back to overview]Eradication Rate (Bacteriological Response, Data Review Committee Assessment)
NCT01189487 (5) [back to overview]Eradication Rate (Bacteriological Response, Investigator Assessment)
NCT01189487 (5) [back to overview]Response Rate (Clinical Response, Data Review Committee Assessment)
NCT01189487 (5) [back to overview]Response Rate (Clinical Response, Investigator Assessment)
NCT01793688 (4) [back to overview]Number of Participants With Treatment-Related Adverse Events
NCT01793688 (4) [back to overview]Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert
NCT01793688 (4) [back to overview]Number of Participants With Treatment-Related Serious Adverse Events
NCT01793688 (4) [back to overview]Clinical Effectiveness Rate by Indication
NCT03445195 (3) [back to overview]Number of Participants With Overall Success
NCT03445195 (3) [back to overview]Clinical Cure
NCT03445195 (3) [back to overview]Microbiologic Eradication
NCT03894046 (2) [back to overview]Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population
NCT03894046 (2) [back to overview]Proportion of Patients With Nephrotoxicity

Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and no Prophylaxis (No Prophylaxis Group).

(NCT00356148)
Timeframe: 1 month

Interventionparticipants (Number)
Prophylaxis Group9
No Prophylaxis Group25

[back to top] [back to top]

Number of Clinically Evaluable (CE) Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit

Investigator assigned clinical response of cure of the cSSSI defined as: resolution of all clinical signs and symptoms of infection (healing of chronic underlying skin ulcer not required) or improvement of signs or symptoms of the infection to such an extent that no further antibacterial therapy was necessary. CE population were those who completed TOC assessment of cure or failure (but not indeterminate) or, in case of premature discontinuation due to lack of efficacy, had completed end of treatment assessment such that assessment of clinical response could be made. (NCT00368537)
Timeframe: up to 6 weeks

Interventionparticipants (Number)
Tigecycline162
Ampicillin-Sulbactam or Amoxicillin-Clavulanate152

[back to top]

Number of Microbiologically Evaluable Patients With Clinical Response of Cure at the Test-of-cure (TOC) Visit

Investigator assigned clinical response of cure of the cSSSI defined as: resolution of all clinical signs and symptoms of infection (healing of chronic underlying skin ulcer not required) or improvement of signs or symptoms of the infection to such an extent that no further antibacterial therapy was necessary. ME population were subjects who were CE and had baseline culture with at least 1 identified isolate that was susceptible to study drug and comparator. TOC performed 8-50 days after last dose of study drug. (NCT00368537)
Timeframe: up to 6 weeks

Interventionparticipants (Number)
Tigecycline96
Ampicillin-Sulbactam or Amoxicillin-Clavulanate77

[back to top]

Inpatient Healthcare Resource Utilization on or Before Test-of-Cure - Number of Patients

Healthcare resource utilization assessment included intensive care unit (ICU) and non-ICU inpatient hospitalization. TOC performed 8-50 days after last dose of study drug. (NCT00368537)
Timeframe: up to 6 weeks

,
Interventionparticipants (Number)
Intensive care unitNon-ICU inpatient hospitalization
Ampicillin-Sulbactam or Amoxicillin-Clavulanate9263
Tigecycline6268

[back to top]

Minimum Inhibitory Concentration (MIC) 50 and 90 by Baseline Isolate

In vitro activity of the study drugs against a range of pathogenic bacteria that cause complicated skin and skin structure infection (cSSSI) were analyzed using MIC. MIC 50 and MIC 90 are the lowest concentrations of a drug that inhibit the growth of 50% and 90% of a microorganism, respectively. TOC performed 8-50 days after last dose of study drug. (NCT00368537)
Timeframe: up to 6 weeks

,
Interventionmcg/mL (Number)
Enterococcus Faecalis MIC50 (n=20,20)Enterococcus Faecalis MIC90 (n=20,20)Escherichia Coli MIC50 (n=29,29)Escherichia Coli MIC90 (n=29,29)Klebsiella Pneumoniae MIC50 (n=13,13)Klebsiella Pneumoniae MIC90 (n=13,13)Staphylococcus Aureus MIC50 (n=176,176)Staphylococcus Aureus MIC90 (n=176,176)Streptococcus Agalactiae MIC50 (n=18,18)Streptococcus Agalactiae MIC90 (n=18,18)Streptococcus Pyogenes MIC50 (n=18,18)Streptococcus Pyogenes MIC90 (n=18,18)
Ampicillin-Sulbactam or Amoxicillin-Clavulanate1.001.008.0032.002.008.002.008.000.120.120.060.06
Tigecycline0.120.250.250.500.502.000.120.250.030.060.030.06

[back to top]

Number of Microbiologically Evaluable Patients by Microbiologic Response at Test-of-Cure (TOC) Visit

Microbiological response assessed at patient level. Eradication=baseline isolate not present in repeat culture from the original infection site; Presumed Eradication=clinical response of cure precluded the availability of a specimen for culture; Persistence=baseline isolate present in repeat culture from the original infection site; Presumed Persistence=culture data not available for patients with a clinical response of failure; Superinfection=culture from the primary infection site had new pathogen not identified as a baseline isolate and clinical response was failure. (NCT00368537)
Timeframe: up to 6 weeks

,
Interventionparticipants (Number)
Eradication + presumed eradicationPersistence + Presumed persistenceSuperinfection
Ampicillin-Sulbactam or Amoxicillin-Clavulanate76231
Tigecycline95252

[back to top]

Number of Participants With Fistula or Delayed Wound Healing Following Palatoplasty

Primary outcomes of fistula or delayed wound healing following palatoplasty were measured in two groups of patients. This outcome measure addresses both objectives noted in the summary of the study description. (NCT00760006)
Timeframe: We anticipate a minimum of less than 2 months to a maximum of 1 year for follow-up will be necessary to document either stage 1 healing or the presence of a palatal fistula in nearly all cases.

,
InterventionParticipants (Count of Participants)
FistulaDelayed Wound Healing
Saline Placebo Arm221
Unasyn Antibiotic Arm318

[back to top]

The Tendency Toward Clinical Improvement (Investigator Assessment)

The number of participants who showed tendency toward clinical improvement based on the assessment of temperature, white blood cell count, C-reactive protein, clinical symptoms on Day 4 and was determined to continue the treatment. (NCT01189487)
Timeframe: Day 4

Interventionpercentage of participants (Number)
Ampicillin Sodium/Sulbactam Sodium100.0

[back to top]

Eradication Rate (Bacteriological Response, Data Review Committee Assessment)

"Eradication Rate was calculated from the following formula, the number of participants assessed as eradication, presumed eradication or microbial substitution over total participants excluding ones assessed as indeterminate multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment." (NCT01189487)
Timeframe: Day 4, End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)

Interventionpercentage of participants (Number)
Day 4 (n=24)End of treatment (n=25)Test of cure (n=24)Long term follow up (n=21)
Ampicillin Sodium/Sulbactam Sodium100.096.091.795.2

[back to top]

Eradication Rate (Bacteriological Response, Investigator Assessment)

"Eradication Rate was calculated from the following formula, the number of participants assessed as eradication , presumed eradication or microbial substitution over total participants excluding ones assessed as indeterminate multiplied by 100. Microbial substitution means the appearance of new pathogens other than the original pathogens in a specimen from the same location with signs and symptoms of infection after the original pathogens were eradicated by treatment." (NCT01189487)
Timeframe: Day 4, End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)

Interventionpercentageof participants (Number)
Day 4 (n=23)End of treatment (n=24)Test of cure (n=23)Long term follow up (n=19)
Ampicillin Sodium/Sulbactam Sodium95.7100.095.7100.0

[back to top]

Response Rate (Clinical Response, Data Review Committee Assessment)

"Response rate was calculated from the following formula, the number of participants assessed as effective over total participants excluding ones assessed as indeterminate multiplied by 100." (NCT01189487)
Timeframe: End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)

Interventionpercentage of participants (Number)
End of treatment (n=39)Test of cure (n=37)Long term follow up (n=36)
Ampicillin Sodium/Sulbactam Sodium97.494.694.4

[back to top]

Response Rate (Clinical Response, Investigator Assessment)

"Response rate was calculated from the following formula, the number of participants assessed as effective over total participants EXCLUDING ones assessed as indeterminate multiplied by 100." (NCT01189487)
Timeframe: End of treatment, Test of cure (7 days after End of treatment), Long term follow up (7 days after Test of cure)

Interventionpercentage of participants (Number)
End of treatment (n=40)Test of cure (n=38)Long term follow up (n=34)
Ampicillin Sodium/Sulbactam Sodium100.0100.0100.0

[back to top] [back to top] [back to top] [back to top]

Clinical Effectiveness Rate by Indication

Clinical effectiveness rate, which was defined as the percentage of participants who achieved clinical effectiveness over the total number of participants with assessable effectiveness evaluation, was presented by each indication (pneumonia, lung abcess and peritorinitis) along with the corresponding exact 2-sided 95% confidence interval. Overall effectiveness of sulbactam sodium/ampicillin sodium was determined by the investigator based on clinical symptoms and examinations at the end of high-dose (>6 g daily) treatment. Clinical effectiveness was assessed according to the following categories: (1) effective, (2) ineffective, or (3) unassessable at the end of treatment. (NCT01793688)
Timeframe: 14 Days

InterventionPercentage of participants (Number)
With Pneumonia (n=856)With Lung Abcess (n=70)With Peritonitis (n=47)
Sulbactam Sodium/Ampicillin Sodium85.178.578.7

[back to top]

Number of Participants With Overall Success

The primary efficacy endpoint for this study was the proportion of patients with an overall success (clinical cure and micro-biologic eradication) for the m-MITT (Micro-biologically Modified Intent-to-Treat) Population at the TOC Visit. (NCT03445195)
Timeframe: From baseline through day 21

InterventionParticipants (Count of Participants)
Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin36
Placebo + Imipenem/Cilastatin17

[back to top]

Clinical Cure

Proportion of patients with a response of clinical cure for the MITT(modified intent to treat), m-MITT (microbiologically modified intent to treat), CE(clinically evaluable), and ME(microbiologically evaluable) populations at the TOC(test of cure) visit. (NCT03445195)
Timeframe: Baseline to day 21

,
InterventionParticipants (Count of Participants)
MITT populationm-MITT populationCE populationME population
Placebo + Imipenem/Cilastatin27212721
Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin52465245

[back to top]

Microbiologic Eradication

Proportion of patients with a response of microbiologic eradication for the m-MITT(microbiologically modified intent to treat) and ME(microbiologically evaluable) populations at the TOC visit (NCT03445195)
Timeframe: Baseline to day 21

,
InterventionParticipants (Count of Participants)
m-MITT populationME population
Placebo + Imipenem/Cilastatin1717
Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin3736

[back to top]

Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population

The primary efficacy endpoint for the study is 28-day all-cause mortality in the CRABC m-MITT population in Part A. (NCT03894046)
Timeframe: 28 Days

InterventionParticipants (Count of Participants)
Part A - Group 112
Part A - Group 220

[back to top]

Proportion of Patients With Nephrotoxicity

The primary safety endpoint for the study is nephrotoxicity, as measured by the Risk-Injury-Failure-Loss-End-stage renal disease (RIFLE) criteria, in the MITT population in Part A. (NCT03894046)
Timeframe: 28 days

InterventionParticipants (Count of Participants)
Part A - Group 112
Part A - Group 232

[back to top]